

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 May 2004 (06.05.2004)

PCT

(10) International Publication Number  
**WO 2004/038005 A2**

- (51) International Patent Classification<sup>7</sup>: C12N
- (21) International Application Number: PCT/US2003/033961
- (22) International Filing Date: 24 October 2003 (24.10.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/421,538 25 October 2002 (25.10.2002) US

MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(ii)) for all designations


**Published:**

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

- (71) Applicant (for all designated States except US): **NORAK BIOSCIENCES, INC.** [US/US]; P.O. Box 14769, Research Triangle Park, NC 27709 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **LOOMIS, Carson, R.** [US/US]; 903 East Oak Drive, Durham, NC 27705 (US). **OAKLEY, Robert, H.** [US/US]; 703 Braden Dr., Durham, NC 27713 (US). **WANG, Shuntai** [CN/US]; 109 Windhover Place, Chapel Hill, NC 27514 (US). **ECKHARDT, Allen, E.** [US/US]; 908 Kimball Drive, Durham, NC 27705 (US).
- (74) Agents: **BAUM, Allen, R.** et al.; Burns, Doane, Swecker & Mathis, L.L.P., P.O. Box 1404, Alexandria, VA 27713 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,

(54) Title: METHODS OF IDENTIFYING REDUCED INTERNALIZATION TRANSMEMBRANE RECEPTOR AGONISTS



(57) Abstract: Described herein are methods of identifying a transmembrane receptor (TMR) agonist and compounds identified by this method. The TMR agonist (TMRA) is capable of activating TMR signaling while exhibiting reduced TMR internalization over a control compound.

WO 2004/038005 A2

## Methods of Identifying Reduced Internalization Transmembrane Receptor Agonists

### FIELD OF THE INVENTION

0001 Methods of identifying Reduced Internalization Transmembrane  
5 Receptor Agonists are disclosed.

### BACKGROUND

0002 Transmembrane receptors (TMRs) are proteins that span  
membranes and have the ability to interact with or bind a ligand, which may  
10 be a hormone, small molecule, lipid, nucleic acid, or peptide, for example. G  
protein-coupled receptors (GPCRs) are cell surface transmembrane proteins  
that translate hormone or ligand binding into intracellular signals, as do most  
TMRs. TMRs, or GPCRs, are found in all animals, insects, and plants.  
TMR, or GPCR, signaling plays a pivotal role in regulating various  
15 physiological functions including phototransduction, olfaction,  
neurotransmission, vascular tone, cardiac output, digestion, pain, and fluid  
and electrolyte balance. GPCRs, although involved in numerous  
physiological functions, share a number of common structural features.  
They contain seven membrane domains bridged by alternating intracellular  
20 and extracellular loops and an intracellular carboxyl-terminal tail of variable  
length.

0003 GPCRs and other transmembrane receptors have been implicated  
in a number of disease states, including, but not limited to: cardiac  
indications such as angina pectoris, essential hypertension, myocardial  
25 infarction, supraventricular and ventricular arrhythmias, congestive heart  
failure, atherosclerosis, renal failure, diabetes, respiratory indications such  
as asthma, chronic bronchitis, bronchospasm, emphysema, airway  
obstruction, upper respiratory indications such as rhinitis, seasonal allergies,  
inflammatory disease, inflammation in response to injury, rheumatoid  
30 arthritis, chronic inflammatory bowel disease, glaucoma, hypergastrinemia,  
gastrointestinal indications such as acid/peptic disorder, erosive esophagitis,

gastrointestinal hypersecretion, mastocytosis, gastrointestinal reflux, peptic ulcer, Zollinger-Ellison syndrome, pain, obesity, bulimia nervosa, depression, obsessive-compulsive disorder, organ malformations (for example, cardiac malformations), neurodegenerative diseases such as  
5 Parkinson's Disease and Alzheimer's Disease, multiple sclerosis, Epstein-Barr infection and cancer.

0004 The magnitude of the physiological responses controlled by TMRs can be linked to the balance between TMR signaling and signal termination.

The signaling of GPCRs and some other TMRs is controlled by a family of  
10 intracellular proteins called arrestins. GPCRs are an example of transmembrane receptors which bind arrestin, activate signaling, and the like. Arrestins bind activated GPCRs, including those that have been agonist-activated and especially those that have been phosphorylated by G protein-coupled receptor kinases (GRKs).

15 0005 Receptors, including GPCRs, have historically been targets for drug discovery and therapeutic agents because they bind ligands, hormones, and drugs with high specificity. Approximately fifty percent of the therapeutic drugs in use today target or interact directly with GPCRs. See e.g., Jurgen Drews, (2000) "Drug Discovery: A Historical Perspective,"  
20 Science 287:1960-1964.

0006 TMRs, of which GPCRs are but one example, may be useful in the methods described herein.

### **TMRs and signaling**

0007 TMRs, or GPCRs, can activate intracellular signaling. GPCRs  
25 recruit and regulate the activity of intracellular heterotrimeric G proteins. The activated receptor typically induces a conformational change in the associated G protein  $\alpha$ -subunit leading to release of GDP followed by binding of GTP. Subsequently, the GTP-bound form of the  $\alpha$ -subunit dissociates from the receptor as well as from the stable  $\beta\gamma$ -dimer. Both the  
30 GTP-bound  $\alpha$ -subunit and the released  $\beta\gamma$ -dimer can modulate several cellular signaling pathways. These include, among others, stimulation or

inhibition of adenylate cyclases and activation of phospholipases, as well as regulation of potassium and calcium channel activity. GPCRs also may not solely act via heterotrimeric G proteins.

5 **Transmembrane receptors (TMRs) and Internalization**

0008 Internalized TMRs, or GPCRs, are not responsive to agonists or ligands. Subsequent to agonist or ligand exposure, initial steps of internalization produce attenuation of the signaling ability of the TMR or GPCR that may involve uncoupling of the GPCR from its cognate  
10 heterotrimeric G-protein. The cellular mechanism mediating initial steps of agonist-specific internalization is a two-step process in which agonist-occupied receptors are phosphorylated by a kinase, for example a GPCR kinase (GRK), and then bind an arrestin protein. TMRs, of which GPCRs are but one example, may bind an arrestin protein, and  
15 subsequently be internalized. The type III TGF-beta receptor is an example of a TMR, other than a GPCR, that binds arrestin, and undergoes subsequent internalization and signaling down-regulation (Chen et al., 2003, Science 301:1394-1397).

0009 It is known, for example, that after agonists bind GPCRs, G-  
20 protein coupled receptor kinases (GRKs) phosphorylate intracellular domains of GPCRs. After phosphorylation, an arrestin protein associates with the GRK-phosphorylated receptor and uncouples the receptor from its cognate G protein. The interaction of the arrestin with the phosphorylated GPCR terminates GPCR signaling, initiates internalization, and produces a  
25 non-signaling receptor.

0010 The arrestin bound to the GPCR targets the GPCR to clathrin-coated pits or other cellular machinery for endocytosis (i.e., internalization) by functioning as an adaptor protein, which links the GPCR to components of the endocytic machinery, such as adaptor protein-2 (AP-2) and clathrin.  
30 The internalized GPCRs are dephosphorylated and are recycled back to the cell surface, or are retained within the cell and degraded. The stability of the interaction of arrestin with the GPCR is one factor that dictates the rate of

GPCR dephosphorylation, and recycling. The involvement of GPCR phosphorylation and dephosphorylation in the internalization process has been exemplified in U.S.S.N. 09/933,844, filed November 5, 2001, the disclosure of which is hereby incorporated by reference in its entirety.

- 5 0011 There is a need for methods to identify compounds that can activate TMR signaling, or GPCR signaling, with reduced internalization of the TMR. Such compounds have increased signaling with decreased signal termination.

### SUMMARY

- 10 0012 The present invention relates to methods of identifying a compound that activates TMR signaling with reduced internalization of the TMR. Considering the importance of modulation of TMR, or GPCR, activity in drug discovery and disease treatment, these methods for the identification of these compounds satisfies a great need.
- 15 0013 This disclosure relates to methods of identifying a compound that activates TMR signaling with reduced internalization of the TMR.

### BRIEF DESCRIPTION OF DRAWINGS

- 0014 The objects and advantages of the invention will be understood by reading the following detailed description in conjunction with the drawings in
- 20 which:
- 0015 Figure 1 is a list of GPCRs that may be used with the present invention.
- 0016 Figure 2 is a list of certain Class A and Class B GPCRs.
- 0017 Figure 3 lists some GPCR agonists or ligands useful in the
- 25 present invention.
- 0018 Figures 4 A-L depict the dose response curves for human GPCR signaling and translocation in CHO cells, in the presence of compounds 1-12, for 30 min, 60 min, and 120 min, in one experiment. Figures 4 M-X depict the dose response curves for human GPCR signaling and
- 30 translocation in CHO cells, in the presence of compounds 1-12, for 30 min, 60 min, and 120 min, in a second experiment.

0019 Figures 5 A-L depict the dose response curves for human GPCR signaling and translocation in U2OS cells, in the presence of compounds 1-12, for 30 min, 60 min, and 120 min, in one experiment. Figures 5 M-X depict the dose response curves for human GPCR signaling and  
5 translocation in U2OS cells, in the presence of compounds 1-12, for 30 min, 60 min, and 120 min, in a second experiment.

0020 Figures 6 A-L depict the dose response curves for rat GPCR signaling and translocation in CHO cells, in the presence of compounds 1-12, for 30 min, 60 min, and 120 min, in one experiment. Figures 6 M-X  
10 depict the dose response curves for rat GPCR signaling and translocation in CHO cells, in the presence of compounds 1-12, for 30 min, 60 min, and 120 min, in a second experiment.

0021 Figures 7 A-L depict the dose response curves for rat GPCR signaling and translocation in U2OS cells, in the presence of compounds 1-12, for 30 min, 60 min, and 120 min, in one experiment. Figures 7 M-X  
15 depict the dose response curves for rat GPCR signaling and translocation in U2OS cells, in the presence of compounds 1-12, for 30 min, 60 min, and 120 min, in a second experiment.

0022 Figure 8 A depicts the dose response curves for MOR signaling and translocation in U2OS cells, in the presence of DAMGO, for 30 min, 60 min, and 120 min, expressed as a % of the maximum response in the presence of morphine. Figure 8 B depicts the dose response curves for MOR signaling and translocation in U2OS cells, in the presence of morphine, for 30 min, 60 min, and 120 min, expressed as a % of the  
25 maximum response in the presence of morphine. Figure 8 C depicts the dose response curves for MOR signaling and translocation in U2OS cells, in the presence of DAMGO, for 30 min, 60 min, and 120 min, expressed as a % of the maximum response in the presence of DAMGO. Figure 8 D depicts the dose response curves for MOR signaling and translocation in  
30 U2OS cells, in the presence of morphine, for 30 min, 60 min, and 120 min, expressed as a % of the maximum response in the presence of DAMGO.

### DETAILED DESCRIPTION

0023 In accordance with the present invention there may be employed conventional molecular biology, microbiology, immunology, and recombinant DNA techniques within the skill of the art. Such techniques are explained  
5 fully in the literature. See, e.g., Sambrook et al, "Molecular Cloning: A Laboratory Manual" (1989); "Current Protocols in Molecular Biology" Volumes I-III [Ausubel, R. M., ed. (1994)]; "Cell Biology: A Laboratory Handbook" Volumes I-III [J. E. Celis, ed. (1994)]; "Current Protocols in Immunology" Volumes I-III [Coligan, J. E., ed. (1994)]; "Oligonucleotide  
10 Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid Hybridization" [B.D. Hames & S.J. Higgins eds. (1985)]; "Transcription And Translation" [B.D. Hames & S.J. Higgins, eds. (1984)]; "Animal Cell Culture" [R.I. Freshney, ed. (2000)]; "Immobilized Cells And Enzymes" [IRL Press, (1986)]; B. Perbal, "A Practical Guide To Molecular Cloning" (1984); *Using Antibodies: A  
15 Laboratory Manual: Portable Protocol No. 1*, Harlow, Ed and Lane, David (Cold Spring Harbor Press, 1998); *Using Antibodies: A Laboratory Manual*, Harlow, Ed and Lane, David (Cold Spring Harbor Press, 1999).

0024 Unless otherwise stated, the following terms used in the specification and claims have the meanings given below:

20 0025 A "DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its either single stranded form, or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA  
25 found, *inter alia*, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand  
30 having a sequence homologous to the mRNA).

0026 "Arrestin" means all types of naturally occurring and engineered variants of arrestin, including, but not limited to, visual arrestin (sometimes

referred to as Arrestin 1), cone arrestin (sometimes referred to as arrestin-4),  $\beta$ -arrestin 1 (sometimes referred to as Arrestin 2), and  $\beta$ -arrestin 2 (sometimes referred to as Arrestin 3). Modified arrestins, for example arrestins that constitutively bind TMRs or GPCRs, are included.

5 0027 "βAR" is a GPCR termed a β-adrenergic receptor.

0028 "Carboxyl-terminal tail" means the carboxyl-terminal tail of a GPCR following membrane span 7. The carboxyl-terminal tail of many GPCRs begins shortly after the conserved NPXXY motif that marks the end of the seventh transmembrane domain (i.e. what follows the NPXXY motif is  
10 the carboxyl-terminal tail of the GPCR). The carboxyl-terminal tail may be relatively long (approximately tens to hundreds of amino acids), relatively short (approximately tens of amino acids), or virtually non-existent (less than approximately ten amino acids). As used herein, "carboxyl-terminal tail" shall mean all three variants (whether relatively long, relatively short, or virtually  
15 non-existent), and may or may not contain palmitoylated cysteine residue(s).

0029 "Class A receptors" preferably do not translocate together with arrestin proteins to endocytic vesicles or endosomes in association with arrestin-GFP in HEK-293 cells.

0030 "Class B receptors" preferably do translocate together with  
20 arrestin proteins to endocytic vesicles or endosomes associated with arrestin-GFP in HEK-293 cells.

0031 "Detectable molecule" or "tag" or "label" means any molecule capable of detection by spectroscopic, photochemical, biochemical, immunochemical, electrical, radioactive, and optical means, including but  
25 not limited to, fluorescence, phosphorescence, and bioluminescence and radioactive decay. Detectable molecules include, but are not limited to, GFP, luciferase, β-galactosidase, rhodamine-conjugated antibody, and the like. Detectable molecules include radioisotopes, epitope tags, affinity labels, enzymes, fluorescent groups, chemiluminescent groups, and the like.

30 Detectable molecules include molecules which are directly or indirectly detected as a function of their interaction with other molecule(s).

Detectable molecules may be used to detect cellular molecules which are otherwise difficult to detect. For example, if detectably labeled, arrestin or a GPCR can be easily detected. The detectable label can be used to determine the localization of the labeled molecule. For example, detectably

5 labeled arrestin or GPCR facilitates the determination of the localization of the molecule, or related molecules, in the plasma membrane, pits, cytosol, endocytic vesicles, or endosomes, for example.

0032 "GFP" means Green Fluorescent Protein which refers to various naturally occurring forms of GFP which may be isolated from natural

10 sources or genetically engineered, as well as artificially modified GFPs. GFPs are well known in the art. See, for example, U.S. Patent Nos. 5,625,048; 5,777,079; and 6,066,476. It is well understood in the art that GFP is readily interchangeable with other fluorescent proteins, isolated from natural sources or genetically engineered, including but not limited to, yellow

15 fluorescent proteins (YFP), red fluorescent proteins (RFP), cyan fluorescent proteins (CFP), blue fluorescent proteins, luciferin, UV excitable fluorescent proteins, or any wave-length in between. As used herein, "GFP" shall mean all fluorescent proteins known in the art.

0033 "Unknown or Orphan Receptor" means a TMR, or a GPCR,

20 whose function and/or ligands are unknown.

0034 Amino acid substitutions may also be introduced to substitute an amino acid with a particularly preferable property. For example, a Cys may be introduced a potential site in order to allow formation of disulfide bridges with another Cys. A His may be introduced as a particularly "catalytic"

25 residue (i.e., His can act as an acid or base and is the most common amino acid in biochemical catalysis). Pro may be introduced because of its particularly planar structure, which induces  $\beta$ -turns in the protein's structure.

0035 Two amino acid sequences are "substantially homologous" when at least about 70% of the amino acid residues (preferably at least about

30 80%, and most preferably at least about 90 or 95%) are identical, or represent conservative substitutions.

0036 "Antagonist(s)" include all agents that interfere with wild-type and/or modified TMR, or GPCR, binding to an agonist, wild-type and/or modified TMR, or GPCR, internalization, wild-type and/or modified TMR, or GPCR, binding arrestin, wild-type and/or modified TMR, or GPCR,

5 endosomal localization, internalization, and the like, including agents that affect the wild-type and/or modified TMRs, including GPCRs, as well as agents that affect other proteins involved in wild-type and/or modified TMR, or GPCR, signaling, internalization, endosomal localization, and the like.

0037 "Modified GPCR" or "modified TMR" means a GPCR or TMR that  
10 has one or more modifications in the amino acid sequence. As such, the GPCR or TMR may be modified in whole or in part. These modifications in the amino acid sequence include mutations of one or more amino acids, insertion of one or more amino acids, deletion of one or more amino acids, and substitutions of one or more amino acids in which one or more amino  
15 acids are deleted and one or more amino acids are added in place of the deleted amino acids. Such modified GPCRs are described herein, as well as in U.S.S.N. 09/993,844 and U.S.S.N. 10/054,616, which are incorporated herein by reference in their entireties.

0038 "GPCR" means G protein-coupled receptor and includes GPCRs  
20 naturally occurring in nature, as well as GPCRs which have been modified.

0039 "TMR" means transmembrane receptor and includes TMRs naturally occurring in nature, as well as TMRs which have been modified. GPCRs are an example of TMRs.

0040 "Internalized TMR" means a TMR that has undergone  
25 internalization. The internalized TMR may be located at any point in the internalization pathway. It presently does not have ability to bind to agonist and activate conventional signaling. The TMR may be a GPCR. The signaling may be G protein signaling.

0041 "Internalization pathway" means any cellular component of the  
30 internalization process, as well as any cellular structure implicated in the internalization process and subsequent processes, including but not limited

to, arrestins, GRKs, GPCRs, AP-2 protein, clathrin, protein phosphatases, and the like. In the methods of assaying of the present invention, the polypeptides may be detected, for example, in the cytoplasm, at a cell membrane, in clathrin-coated pits, in endocytic vesicles, endosomes, any  
5 stages in between, and the like.

0042 "TMR signaling" means TMR induced activation of signaling. This may result in, for example, cAMP production. The TMR may be a GPCR. The signaling may be G protein signaling.

0043 "G protein-coupled receptor kinase" (GRK) includes any kinase  
10 that has the ability to phosphorylate a GPCR. Splice variants, biologically active fragments, modified GRKs, and GRKs from animals and other organisms are included.

0044 "*Homo sapiens* TMR" means a naturally occurring TMR in a *Homo sapiens*. The TMR may be a GPCR.

15 0045 "Naturally occurring TMR" means a TMR that is present in nature. The TMR may be a GPCR.

0046 "Odorant ligand" means a ligand compound that, upon binding to a receptor, leads to the perception of an odor including a synthetic compound and/or recombinantly produced compound including agonist and  
20 antagonist molecules.

0047 "Odorant receptor" means a receptor protein normally found on the surface of olfactory neurons which, when activated (normally by binding an odorant ligand) leads to the perception of an odor.

0048 "Modulation" includes at least an up-regulation or down-regulation  
25 of the expression, or an increase or decrease in activity of a protein. Modulation of a protein includes the up-regulation, down-regulation, increase or decrease in activity of a protein or compound that regulates a protein. Modulation also includes the regulation of the gene, the mRNA, or any other step in the synthesis of the protein of interest.

30 0049 An "overexpressed" protein refers to a protein that is expressed at levels greater than wild-type expression levels.

0050 "Modified GRK" means a GRK that has one or more modifications in the amino acid sequence at the C-terminus of the GRK. The modified GRK constitutively localizes to the plasma membrane. Preferably, the GRK is modified by the addition of a CAAX motif.

5 0051 "CAAX" motif means a four amino acid sequence, wherein C is cysteine; A is an aliphatic amino acid; and X is the C-terminal amino acid of the protein.

0052 A "constitutive" activity means an activity that occurs in the absence of agonist. For example, the modified GRK constitutively localizes  
10 to the plasma membrane means that the modified GRK localizes to the plasma membrane in the absence of agonist.

0053 "Reduced Internalization" means that the TMR, or GPCR, internalization is reduced or delayed as compared with the TMR, or GPCR, internalization activated by a control compound. The control compound may  
15 be a natural agonist or natural ligand of the TMR, but may be any other compound used as a control. Reduced internalization may be demonstrated by a number of factors. For example, reduced internalization may be demonstrated by a decrease in the Max of internalization of the receptor as compared to the internalization stimulated by a natural agonist or natural  
20 ligand of the TMR. In another example, reduced internalization may be demonstrated by an increase in the EC50 of internalization of the TMR as compared to the internalization stimulated by a natural agonist or natural ligand of the TMR. In a further example, if the amount of compound required to activate internalization is greater than the amount of natural  
25 agonist or natural ligand required to activate internalization, then the internalization would be reduced. In yet another example, if the length of time that the TMR is required to be exposed to the compound in order to activate internalization is greater than the length of time that the TMR is required to be exposed to a natural agonist or natural ligand in order to  
30 activate internalization, then the internalization would be reduced.

0054 "EC50" represents the median effective concentration of a

compound; the smallest concentration required to produce 50% of a maximal stated effect.

0055 The "stated effect" means the effect of interest. The stated effect, for example, may be activation of signaling, inhibition of signaling, amount of  
5 signaling, activation of internalization, inhibition of internalization, amount of internalization, or ligand binding.

0056 A "Max" represents the maximal stated effect. The Max may be empirically determined or extrapolated. Bmax and Vmax are examples of Max. For example, Max may be the maximal response as plotted on a  
10 response curve. For example, in a measurement of signaling, cAMP production may be plotted with respect to different concentrations of a test compound to yield a dose response curve; the Max represents the maximal cAMP production on the dose response curve. As an additional example, in a measurement of translocation, translocation may be plotted with respect to  
15 different concentrations of a test compound to yield a dose response curve; the Max represents the maximal translocation on the dose response curve.

0057 A "control" compound is a compound against which the test compound is compared. Preferably, the control compound in the present invention may activate and internalize a TMR, or a GPCR. Preferably, the  
20 control compound may be an agonist or ligand of a TMR, or a GPCR.

0058 A "dose response curve" represents a stated effect in the presence of different concentrations of a compound. In the dose response curves in the present invention, the stated effect is preferably the signaling or internalization of a TMR, or a GPCR.

25 0059 "Measuring translocation of a TMR" means detection of the localization of a TMR in a cell. The TMR may be a GPCR. Preferably, the TMR, or GPCR, is detected by visualizing the TMR, arrestin, GRK, or another molecule. The molecule to be detected may be detectably labeled. Examples of detectably labeled molecules are described herein.  
30 Preferably, the molecule is localized at the cell membrane, in pits, endosomes, endocytic vesicles, and/or in the cytosol. Methods of

monitoring translocation include Transfluor, BRET, FRET, polarization microscopy, evanescent wave excitation microscopy, and standard or confocal microscopy. Useful TMRs, GPCRs, methods, and methods of detection, for example, are as described herein, in U.S.S.N. 08/869,568  
5 (now Issued U.S. Patent No. 5,891,646), 09/233,530 (now Issued U.S. Patent No. 6,110,693), 09/469,554 (now Issued U.S. Patent No. 6,528,271), 10/054,616, 09/993,844, 10/095,620, 10/101,235, 09/631,468, 10/141,725, 10/161,916, 09/772,644, 10/336,276, 60/421,538, 60/442,403, 60/470,325, 60/401,698, 60/275,339, 60/263,406, 60/245,772, 60,260,363, 60/295,945,  
10 60/393,789, and 60/379,986, and PCT applications PCT/US03/20838, and PCT/US03/14581 which are incorporated by reference herein.

0060 "Quantitatively determining" internalization can include any analytical method of measuring amount of TMR or GPCR internalization, including for example measuring the intensity of pixels, amount of  
15 fluorescence, EC50, Max, dose response curve, or any other quantitative analysis for comparison known to those of skill in the art. Examples of quantitatively determining internalization are described herein. Various methods of detection, including but not limited to those as described herein, may be used for quantitatively determining internalization.

20 0061 A "TMRA" means a transmembrane receptor (TMR) agonist, which is capable of activating TMR signaling while exhibiting reduced TMR internalization over a control compound. The internalization is reduced if the TMR internalization in the presence of the test compound is reduced as compared to the TMR internalization in the presence of a control compound.  
25 The signaling is activated if the TMR signaling in the presence of the test compound is activated as compared to in the absence of agonist.

0062 There is a need for methods of identifying a compound that activates TMR or GPCR signaling with reduced internalization of the TMR or GPCR. Such a compound may increase signaling in response to a given  
30 dose of compound, decrease signal termination, and maintain responsiveness of a given TMR or GPCR to a given dose of compound.

0063 The present invention relates to methods of screening for a TMRA. Methods of determining if a compound activates signaling but has altered internalization properties are included.

0064 TMRA's are useful for a variety of reasons. While compounds which activate signaling and also activate internalization pathways are known, many of these have less than desirable characteristics, including certain side effects. Increased internalization of TMRs would result in fewer receptors available at the membrane or cell surface for interaction with agonist, which may be over repeated dosage. Reduced internalization of TMRs would result in more receptors available at the membrane or cell surface for interaction with agonist or TMRA. This reduced internalization may decrease the amount and/or frequency of agonist or TMRA that is necessary to activate signaling. Methods of identifying TMRA's are necessary. Methods of identifying these compounds would be useful in the treatment of numerous diseases.

0065 The present invention utilizes quantitative measurements of internalization. The quantitative measurements of internalization are necessary in the methods of identifying reduced internalization agonists as described herein.

#### 20 **Methods of quantitating TMR signaling**

0066 TMR or GPCR signaling may be quantitated by any of a number of indicators of TMR or GPCR signaling. These include quantitating the activity of members of any of a number of signaling pathways, GPCR dimerization, and the like. As used herein, a "signaling pathway" refers to the modulation (e.g., stimulation or inhibition) of a cellular function/activity upon the binding of a ligand to the TMR or GPCR. Examples of such functions include mobilization of intracellular molecules that participate in a signal transduction pathway, e.g., phosphatidylinositol 4,5-bisphosphate, inositol 1,4,5-triphosphate, and adenylate cyclase; polarization of the plasma membrane; production or secretion of molecules; alteration in the structure of a cellular component; cell proliferation, e.g., synthesis of DNA; cell

migration; cell differentiation; and cell survival.

0067 The specific pathway to be measured may depend on the specific TMR or GPCR of interest. Many methods of quantitating the activity of members of signaling pathways are known to one of skill in the art.

5 0068 When screening for bioactivity of compounds, intracellular second messenger generation can be measured directly. A variety of intracellular effectors have been identified as being G-protein-regulated, including cAMP, cyclic GMP, Calcium, a lipid, phosphatidylinositol, a hydrogen ion, an ion transport molecule, and the like. In addition, G proteins interact with a range  
10 of ion channels and are able to inhibit certain voltage-sensitive  $\text{Ca}^{++}$  transients, as well as stimulating cardiac  $\text{K}^+$  channels. Additionally, enzymes such as adenylyl cyclase, phosphodiesterase, phospholipase C, protein kinase, phospholipase  $\text{A}_2$ , and the like may be measured.

0069 In one embodiment, the GTPase enzymatic activity by G proteins  
15 can be measured in plasma membrane preparations by determining the breakdown of  $\gamma^{32}\text{P}$  GTP using techniques that are known in the art (For example, see Signal Transduction: A Practical Approach. G. Milligan, Ed. Oxford University Press, Oxford England). When receptors that modulate cAMP are tested, it will be possible to use standard techniques for cAMP  
20 detection, such as competitive assays which quantitate [ $^3\text{H}$ ]cAMP in the presence of unlabelled cAMP.

0070 "Cyclic AMP turnover and metabolism", the molecules involved in the turnover and metabolism of cyclic AMP (cAMP) as well as to the activities of these molecules, can be measured. Cyclic AMP is a second  
25 messenger produced in response to ligand-induced stimulation of certain TMRs or G protein coupled receptors. In the cAMP signaling pathway, binding of a ligand to a TMR or GPCR can lead to the activation of the enzyme adenylyl cyclase, which catalyzes the synthesis of cAMP. The newly synthesized cAMP can in turn activate a cAMP-dependent protein kinase.  
30 This activated kinase can phosphorylate a voltage-gated potassium channel protein, or an associated protein, and lead to the inability of the potassium

channel to open during an action potential. The inability of the potassium channel to open results in a decrease in the outward flow of potassium, which normally repolarizes the membrane of a neuron, leading to prolonged membrane depolarization.

5 0071 Certain receptors stimulate the activity of phospholipase C which stimulates the breakdown of phosphatidylinositol 4,5, biphosphate to 1,4,5-IP<sub>3</sub> (which mobilizes intracellular Ca<sup>++</sup>) and diacylglycerol (DAG) (which activates protein kinase C). Inositol lipids can be extracted and analyzed using standard lipid extraction techniques. DAG can also be measured using  
10 thin-layer chromatography. Water soluble derivatives of all three inositol lipids (IP<sub>1</sub>, IP<sub>2</sub>, IP<sub>3</sub>) can also be quantitated using radiolabelling techniques or HPLC.

0072 "Phosphatidylinositol turnover and metabolism", the molecules involved in the turnover and metabolism of phosphatidylinositol 4,5-  
15 bisphosphate (PIP<sub>2</sub>) as well as to the activities of these molecules, can also be measured. PIP<sub>2</sub> is a phospholipid found in the cytosolic leaflet of the plasma membrane. Binding of ligand to the receptor activates, in some cells, the plasma-membrane enzyme phospholipase C that in turn can hydrolyze PIP<sub>2</sub> to produce 1,2-diacylglycerol (DAG) and inositol 1,4,5-triphosphate  
20 (IP<sub>3</sub>). Once formed IP<sub>3</sub> can diffuse to the endoplasmic reticulum surface where it can bind an IP<sub>3</sub> receptor, e.g., a calcium channel protein containing an IP<sub>3</sub> binding site. IP<sub>3</sub> binding can induce opening of the channel, allowing calcium ions to be released into the cytoplasm. IP<sub>3</sub> can also be phosphorylated by a specific kinase to form inositol 1,3,4,5-tetraphosphate  
25 (IP<sub>4</sub>), a molecule which can cause calcium entry into the cytoplasm from the extracellular medium. IP<sub>3</sub> and IP<sub>4</sub> can subsequently be hydrolyzed very rapidly to the inactive products inositol 1,4-biphosphate (IP<sub>2</sub>) and inositol 1,3,4-triphosphate, respectively. These inactive products can be recycled by the cell to synthesize PIP<sub>2</sub>. The other second messenger produced by the  
30 hydrolysis of PIP<sub>2</sub>, namely 1,2-diacylglycerol (DAG), remains in the cell membrane where it can serve to activate the enzyme protein kinase C.

Protein kinase C is usually found soluble in the cytoplasm of the cell, but upon an increase in the intracellular calcium concentration, this enzyme can move to the plasma membrane where it can be activated by DAG. The activation of protein kinase C in different cells results in various cellular responses such as the phosphorylation of glycogen synthase, or the phosphorylation of various transcription factors, e.g., NF- $\kappa$ B. The language "phosphatidylinositol activity", as used herein, refers to an activity of PIP<sub>2</sub> or one of its metabolites.

0073 The mobilization of intracellular calcium or the influx of calcium from outside the cell can be measured using standard techniques. The choice of the appropriate calcium indicator, fluorescent, bioluminescent, metallochromic, or Ca<sup>++</sup>-sensitive microelectrodes depends on the cell type and the magnitude and time constant of the event under study (Borle (1990) Environ Health Perspect 84:45-56). As an exemplary method of Ca<sup>++</sup> detection, cells could be loaded with the Ca<sup>++</sup> sensitive fluorescent dye fura-2 or indo-1, using standard methods, and any change in Ca<sup>++</sup> measured using a fluorometer.

0074 Another exemplary high throughput calcium assay involves induction of a reporter gene operatively linked to a calcium-responsive promoter. In this method, a calcium flux resulting from the activation of a TMR or GPCR turns on the promoter which subsequently drives the expression of a reporter gene encoding a protein with an enzymatic activity that can be easily detected, preferably by a colorimetric or fluorescent assay. Commonly used reporter proteins include:  $\beta$ -galactosidase,  $\beta$ -lactamase, chloramphenicol acetyltransferase (CAT), luciferase, green fluorescent protein (GFP) and its derivatives, among others. Reporter proteins can also be linked to other proteins whose expression is dependent upon the stimulation of TMRs or GPCRs. An illustrative example would be a fusion protein comprising luciferase sequence in frame with the open-reading frame of nuclear factor of activated T cells (NFAT). Since the transcription of NFAT requires the co-activation of calcium and protein

kinases C signaling pathways acting downstream of TMRs or GPCRs, an effective coupling of heterotrimeric G protein to the receptors can then be measured by assaying NFAT-mediated luciferase activity. This system has been employed to demonstrate a carbachol dependent luciferase response  
5 in cells co-expressing muscarinic m3 receptor and chimeric  $\alpha_q$  mutant i5q (Boss et al., J. Biol. Chem., 271: 10429-10482, 1996). In practice of this method, a preferred host cell is one of lymphoid or neuronal origin, such as Jurkat cells and pheochromocytoma PC12 cells. However, the choice of host cells is not limited to these two types, as NFAT and NFAT isoforms are  
10 present in a variety of cells including endothelial and myeloid cells (id).

0075 Reporter gene based assays of this invention measure the end stage of the above described cascade of events, e.g., transcriptional modulation. Accordingly, in practicing one embodiment of the assay, a reporter gene construct is inserted into the reagent cell in order to generate  
15 a detection signal dependent on receptor signaling. Typically, the reporter gene construct will include a reporter gene in operative linkage with one or more transcriptional regulatory elements responsive to the signal transduction activity of the target receptor, with the level of expression of the reporter gene providing the receptor-dependent detection signal. The  
20 amount of transcription from the reporter gene may be measured using any method known to those of skill in the art to be suitable. For example, specific mRNA expression may be detected using Northern blots or specific protein product may be identified by a characteristic stain or an intrinsic activity.

0076 Also, the activation of phospholipase A2 can easily be quantitated  
25 using known techniques, including, for example, the generation of arachadonate in the cell.

0077 In the case of certain receptors, it may be desirable to screen for changes in cellular phosphorylation. Such assay formats may be useful when the receptor of interest is a receptor tyrosine kinase. For example,  
30 yeast transformed with the FGF receptor and a ligand which binds the FGF receptor could be screened using colony immunoblotting (Lyons and Nelson

(1984) Proc. Natl. Acad. Sci. USA 81:7426-7430) using anti-phosphotyrosine. In addition, tests for phosphorylation could be useful when a receptor which may not itself be a tyrosine kinase, activates protein kinases that function downstream in the signal transduction pathway.

5 Likewise, it is noted that protein phosphorylation also plays a critical role in cascades that serve to amplify signals generated at the receptor. Multi-kinase cascades allow not only signal amplification but also signal divergence to multiple effectors that are often cell-type specific, allowing a growth factor to stimulate mitosis of one cell and differentiation of another.

10 0078 One such cascade is the MAP kinase pathway that appears to mediate both mitogenic, differentiation and stress responses in different cell types. Stimulation of growth factor receptors results in Ras activation followed by the sequential activation of c-Raf, MEK, and p44 and p42 MAP kinases (ERK1 and ERK2). Activated MAP kinase then phosphorylates

15 many key regulatory proteins, including p90 RSK and Elk-1 that are phosphorylated when MAP kinase translocates to the nucleus. Homologous pathways exist in mammalian and yeast cells. For instance, an essential part of the *S. cerevisiae* pheromone signaling pathway is comprised of a protein kinase cascade composed of the products of the STE11, STE7, and

20 FUS3/KSS1 genes (the latter pair are distinct and functionally redundant). Accordingly, phosphorylation and/or activation of members of this kinase cascade can be detected and used to quantitate receptor engagement. Phosphotyrosine specific antibodies are available to measure increases in tyrosine phosphorylation and phospho-specific antibodies are commercially

25 available (New England Biolabs, Beverly, Mass.).

0079 The response mediated by the receptor protein depends on the type of cell. For example, in some cells, binding of a ligand to the receptor protein may stimulate an activity such as release of compounds, gating of a channel, cellular adhesion, migration, differentiation, etc., through

30 phosphatidylinositol or cyclic AMP metabolism and turnover while in other cells, the binding of the ligand will produce a different result. Regardless of

the cellular activity/response modulated by the receptor protein, it is universal that the protein is a TMR or GPCR and interacts with G proteins to produce one or more secondary signals, in a variety of intracellular signal transduction pathways, e.g., through phosphatidylinositol or cyclic AMP metabolism and turnover, in a cell.

0080 The signaling assays may use spectrally-encoded assay bead systems. More than one measure of TMR or GPCR activation may be determined; they may be measured, for example, sequentially or in parallel.

0081 Modified methods for detecting receptor-mediated signal transduction exist and one of skill in the art will recognize suitable methods that may be used to substitute for the example methods listed.

#### **Methods of measuring internalization**

0082 Methods of detecting internalization are useful in the methods of the present invention. Such methods that are detected quantitatively are preferred. Methods that are optically detectable and quantifiable are preferred. Any method that will measure internalization of the TMR or GPCR by monitoring the localization of the TMR or GPCR or any molecule that interacts with the TMR or GPCR in the internalization pathway may be used. Examples include Transfluor, BRET, FRET.

0083 Certain methods of detection useful in the present invention are described in U.S. patent number 5,891,646, U.S. patent number 6,110,693, U.S.S.N. 09/631,468, U.S.S.N. 10/141,725, U.S.S.N. 10/161,916, 09/469,554, U.S.S.N. 09/772,644, U.S.S.N. 09/993,844, U.S.S.N. 10/054,616, U.S.S.N. 10/095,620, U.S.S.N. 10/101,235, U.S. provisional application 60/393,789, U.S. provisional application 60/379,986, and U.S. provisional application 60/401,698, which are hereby incorporated by reference in their entireties. Other methods useful in the present invention are described in U.S.S.N. 09/759,152, U.S.S.N. 09/654,499, WO 99/66324, WO 01/46691, WO 01/46694, WO 98/00715, and WO 02/46763.

0084 Methods of detecting the intracellular location of the detectably labeled arrestin, the intracellular location of a detectably labeled TMR or

GPCR, or interaction of the detectably labeled arrestin, or other member of a TMR or GPCR/arrestin complex with a TMR or GPCR or any other cell structure, including for example, the concentration of arrestin or TMR or GPCR at a cell membrane, colocalization of arrestin with TMR or GPCR in endosomes, and concentration of arrestin or TMR or GPCR in clathrin coated pits, and the like, will vary dependent upon the detectable molecule(s) used.

0085 One skilled in the art readily will be able to devise detection methods suitable for the detectable molecule(s) used. For optically detectable molecules, any optical method may be used where a change in the fluorescence, bioluminescence, or phosphorescence may be measured due to a redistribution or reorientation of emitted light. Such methods include, for example, polarization microscopy, BRET, FRET, evanescent wave excitation microscopy, and standard or confocal microscopy.

0086 In a preferred embodiment arrestin may be conjugated to GFP and the arrestin GFP conjugate may be detected by confocal microscopy. In another preferred embodiment, arrestin may be conjugated to a GFP and the TMR or GPCR may be conjugated to an immunofluorescent molecule, and the conjugates may be detected by confocal microscopy. In an additional preferred embodiment, arrestin may be conjugated to a GFP and the carboxy terminus of the TMR or GPCR may be conjugated to a luciferase and the conjugates may be detected by bioluminescence resonance emission technology. In a further preferred embodiment arrestin may be conjugated to a luciferase and TMR or GPCR may be conjugated to a GFP, and the conjugates may be detected by bioluminescence resonance emission technology. In a further preferred embodiment, arrestin may be conjugated to a detectable molecule fragment (or portion, domain, and the like), TMR or GPCR may be conjugated to a detectable molecule fragment (or portion, domain, and the like), and the interaction of the two fragments can be detected. In a further preferred embodiment, the TMR or GPCR or arrestin may be labeled with a detectable molecule which is specifically

detectable upon localization at certain cellular locations. The methods of the present invention are directed to detecting TMR or GPCR activity. The methods of the present invention allow enhanced monitoring of the GPCR pathway in real time.

5 0087 In a preferred embodiment, the localization pattern of the detectable molecule is determined. In a further preferred embodiment, alterations of the localization pattern of the detectable molecule may be determined. The localization pattern may indicate cellular distribution of the detectable molecule. Certain methods of detection are described in  
10 U.S.S.N. 10/095,620, filed March 12, 2002, which claims priority to U.S. Provisional Patent Application No: 60/275,339, filed March 13, 2001, the contents of which are incorporated by reference in their entirety. The quantitation of the detectable molecules is also described in U.S.S.N. 10/161,916.

15 0088 Molecules may also be detected by their interaction with another detectably labeled molecule, such as an antibody.

0089 Additional methods of quantitating internalization may be used in accordance with the present invention.

#### 20 **Methods of identifying a compound that modulates a TMR or GPCR signaling and/or internalization response**

0090 A method of identifying a TMRA is described below. The TMRA is capable of activating TMR signaling while reducing TMR internalization. The method includes providing a cell including at least one TMR or a biologically active fragment thereof. The cell may also include arrestin or biologically  
25 active fragments thereof, and/or GRK or biologically active fragments thereof. A component or components of the cell may be detectably labeled.

The label may be detectable as the result of an interaction with another detectably labeled molecule, or the like. The detectably labeled molecule may be detected at the plasma membrane, in endosomes, endocytic  
30 vesicles, or in the cytosol, for example. The detectable molecule may be a radioisotope, an epitope tag, an affinity label, an enzyme, a fluorescent

group, or a chemiluminescent group, for example. The method may include the additional steps of providing a agonist or ligand of a TMR, and modifying the agonist or ligand, for example.

0091 The TMR may be a GPCR. Certain GPCRs useful in the present invention are listed in Figure 1. The GPCR may be a class A receptor, a  
5 class B receptor, a  $\mu$  opioid,  $\beta_1$ AR,  $\beta_2$ AR, or dopamine receptor, for example. Certain ligands or agonists useful in the present invention are listed in Figure 3, for example. The compound may be a modified natural ligand or natural agonist. The compound may be a known pharmaceutically  
10 relevant compound, or may be derived from a known pharmaceutically relevant compound. The cell may be exposed to a compound or compounds. The compound or compounds may be derived from a natural ligand or natural agonist. The compound or compounds may be present in a compound library.

15 0092 The signaling may be measured. Certain methods of measuring signaling are described herein, but other methods of measuring signaling may also be used. The measurement of the signaling may be useful in a quantitative determination of whether signaling is activated. A dose response curve for signaling may be determined. Signaling may be  
20 quantitated by measuring an intracellular effector, wherein said effector may be cAMP, cyclic GMP, Calcium, a lipid, phosphatidylinositol, a hydrogen ion, or an ion transport molecule. Signaling in the presence of the compound may be compared to signaling in the absence of compound to determine if the signaling is activated. The signaling may be activated for a longer time  
25 period after stimulation by the TMRA than the length of time of activation after stimulation by the natural ligand or natural agonist.

0093 The internalization may be measured. Certain methods of measuring internalization are described herein, but other methods of measuring internalization may also be used. The measurement of the  
30 internalization may be useful in a quantitative determination of whether internalization is reduced. The internalization may be reduced as compared

to the TMRA internalization in the presence of a control compound. A dose response curve for signaling may be determined.

0094 Agonists and ligands of TMRs may be modified. Such modifications may result in modified chemical and/or physical properties of the compounds. The modified agonists and ligands may be analyzed by  
5 methods of the present invention to identify a TMRA. The modified agonists and ligands may be used to create a panel of compounds. This panel of compounds may be used in the methods as described herein to identify a TMRA.

10 0095 The TMR or GPCR sequence in a cell of the methods described herein may be a human TMR or GPCR, rat TMR or GPCR, mouse TMR or GPCR, pig TMR or GPCR, primate TMR or GPCR, or a TMR or GPCR from any species. For certain TMRs or GPCRs, the TMR or GPCR from a specific species may be preferred in the methods of the present invention.  
15 The methods of the present invention may be repeated; the repeat of method may use cells containing TMRs or GPCRs from different species than in the cells of the first method. A test compound may have TMRA properties in a method using cells including TMRs or GPCRs from a specific species. The same test compound may be a TMRA for TMRs or GPCRs of  
20 a certain species, but may or may not be a TMRA for the same TMR or GPCR of a different species. Repeating the methods may be useful to determine the preferred TMR or GPCR species for use in methods using cells containing that TMR or GPCR.

#### **Vectors and nucleic acids, host cells for protein expression**

25 0096 As is well known in the art, DNA sequences may be expressed by operatively linking them to an expression control sequence in an appropriate expression vector and employing that expression vector to transform an appropriate unicellular host. The transforming DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome  
30 of the cell.

0097 Such operative linking of a DNA sequence of this invention to an

expression control sequence, of course, includes, if not already part of the DNA sequence, the provision of an initiation codon, ATG, in the correct reading frame upstream of the DNA sequence.

0098 A wide variety of host/expression vector combinations may be  
5 employed in expressing the DNA sequences described herein. Useful  
expression vectors, for example, may consist of segments of chromosomal,  
non-chromosomal and synthetic DNA sequences. Suitable vectors include  
derivatives of SV40 and known bacterial plasmids, e.g., *E. coli* plasmids col  
EI, pCR1, pBR322, pMB9 and their derivatives, plasmids such as RP4;  
10 phage DNAs, e.g., the numerous derivatives of phage  $\lambda$ , e.g., NM989, and  
other phage DNA, e.g., M13 and filamentous single stranded phage DNA;  
yeast plasmids such as the 2 $\mu$  plasmid or derivatives thereof; vectors useful  
in eukaryotic cells, such as vectors useful in insect or mammalian cells;  
vectors derived from combinations of plasmids and phage DNAs, such as  
15 plasmids that have been modified to employ phage DNA or other expression  
control sequences; and the like.

0099 Any of a wide variety of expression control sequences --  
sequences that control the expression of a DNA sequence operatively linked  
to it -- may be used in these vectors to express the DNA sequences in this  
20 invention. Such useful expression control sequences include, for example,  
the early or late promoters of SV40, CMV, vaccinia, polyoma or adenovirus,  
the lac system, the trp system, the TAC system, the TRC system, the LTR  
system, the major operator and promoter regions of phage  $\lambda$ , the control  
regions of fd coat protein, the promoter for 3-phosphoglycerate kinase or  
25 other glycolytic enzymes, the promoters of acid phosphatase (e.g., Pho5),  
the promoters of the yeast  $\alpha$ -mating factors, and other sequences known to  
control the expression of genes of prokaryotic or eukaryotic cells or their  
viruses, and various combinations thereof.

00100 A wide variety of unicellular host cells are also useful in  
30 expressing the DNA sequences described herein. These hosts may include  
well known eukaryotic and prokaryotic hosts, such as strains of *E. coli*,

*Pseudomonas*, *Bacillus*, *Streptomyces*, fungi such as yeasts, plant cells, nematode cells, and animal cells, such as HEK-293, U2OS, CHO, RI.I, B-W and L-M cells, African Green Monkey kidney cells (e.g., COS 1, COS 7, BSC1, BSC40, and BMT10), insect cells (e.g., Sf9), and human cells and  
5 plant cells in tissue culture. In one aspect of the present invention, the host cells include a GRK-C20 and an arrestin. In a further aspect of the present invention, the host cells include a GRK, an arrestin, and a GPCR.

00101 It will be understood that not all vectors, expression control sequences and hosts will function equally well to express the DNA  
10 sequences described herein. Neither will all hosts function equally well with the same expression system. However, one skilled in the art will be able to select the proper vectors, expression control sequences, and hosts without undue experimentation to accomplish the desired expression without departing from the scope of this invention. For example, in selecting a  
15 vector, the host must be considered because the vector must function in it. The vector's copy number, the ability to control that copy number, and the expression of any other proteins encoded by the vector, such as antibiotic markers, will also be considered.

00102 In selecting an expression control sequence, a variety of factors  
20 will normally be considered. These include, for example, the relative strength of the system, its controllability, and its compatibility with the particular DNA sequence or gene to be expressed, particularly as regards potential secondary structures. Suitable unicellular hosts will be selected by consideration of, e.g., their compatibility with the chosen vector, their  
25 secretion characteristics, their ability to fold proteins correctly, and their fermentation requirements, as well as the toxicity to the host of the product encoded by the DNA sequences to be expressed, and the ease of purification of the expression products.

00103 Considering these and other factors a person skilled in the art will  
30 be able to construct a variety of vector/expression control sequence/host combinations that will express the DNA sequences described herein on

fermentation or in large scale animal culture.

00104 It is further intended that analogs may be prepared from nucleotide sequences of the protein complex/subunit. Analogs, such as fragments, may be produced, for example, by pepsin digestion. Other  
5 analogs, such as muteins, can be produced by standard site-directed mutagenesis of coding sequences. Analogs exhibiting biological activity, such as small molecules, whether functioning as promoters or inhibitors, may be identified by known *in vivo* and/or *in vitro* assays.

00105 As mentioned above, a DNA sequence can be prepared  
10 synthetically rather than cloned. The DNA sequence can be designed with the appropriate codons for the amino acid sequence. In general, one will select preferred codons for the intended host if the sequence will be used for expression. The complete sequence is assembled from overlapping oligonucleotides prepared by standard methods and assembled into a  
15 complete coding sequence. See, e.g., Edge, Nature, 292:756 (1981); Nambair et al., Science, 223:1299 (1984); Jay et al., J. Biol. Chem., 259:6311 (1984).

00106 Synthetic DNA sequences allow convenient construction of genes which will express analogs or "muteins". Alternatively, DNA encoding  
20 muteins can be made by site-directed mutagenesis of native or modified genes or cDNAs, and muteins can be made directly using conventional polypeptide synthesis.

00107 A general method for site-specific incorporation of unnatural amino acids into proteins is described in Christopher J. Noren, Spencer J.  
25 Anthony-Cahill, Michael C. Griffith, Peter G. Schultz, Science, 244:182-188 (April 1989). This method may be used to create analogs with unnatural amino acids.

00108 Additional motifs, such as epitope tags or sequences to aid in purification, may be incorporated into the nucleic acids. Preferably, the  
30 nucleic acids encoding the motifs may be at the 5' or 3' end of the nucleic acid, resulting in the presence of the motif at the N or C terminus of the

protein.

00109 The cells used in the methods described herein may comprise a conjugate of an arrestin protein and a detectable molecule. In these methods, the cells may also comprise a conjugate of a GPCR and a  
5 detectable molecule.

00110 The GPCR may be modified to have enhanced phosphorylation by a GRK. The GPCR may be  $\beta_2$ AR(Y326A), a GPCR listed in Figure 1, an orphan GPCR, a modified GPCR, a taste receptor, a Class A GPCR, a Class B GPCR, a mutant GPCR, or a biologically active fragment thereof.

10 00111 All forms of arrestin, naturally occurring and engineered variants, including but not limited to, visual arrestin,  $\beta$ arrestin 1 and  $\beta$ arrestin 2, may be used in the present invention.

00112 Detectable molecules that may be used to conjugate with the arrestin include, but are not limited to, molecules that are detectable by  
15 spectroscopic, photochemical, biochemical, immunochemical, electrical, radioactive, and optical means, including but not limited to bioluminescence, phosphorescence, and fluorescence. Detectable molecules include, but are not limited to, GFP, luciferase,  $\beta$ -galactosidase, rhodamine-conjugated antibody, and the like. Detectable molecules include radioisotopes, epitope  
20 tags, affinity labels, enzymes, fluorescent groups, chemiluminescent groups, and the like. Detectable molecules include molecules which are directly or indirectly detected as a function of their interaction with other molecule(s). These detectable molecules should be a biologically compatible molecule and should not compromise the ability of the arrestin to interact with the  
25 GPCR system and the interaction of the arrestin with the GPCR system must not compromise the ability of the detectable molecule to be detected. Preferred detectable molecules are optically detectable molecules, including optically detectable proteins, such that they may be excited chemically, mechanically, electrically, or radioactively to emit fluorescence,  
30 phosphorescence, or bioluminescence. More preferred detectable molecules are inherently fluorescent molecules, such as fluorescent

proteins, including, for example, Green Fluorescent Protein (GFP). The detectable molecule may be conjugated to the arrestin protein by methods as described in Barak et al. (U.S. Patent Nos. 5,891,646 and 6,110,693). The detectable molecule may be conjugated to the arrestin at the front-end,  
5 at the back-end, or in the middle.

00113 The TMR or GPCR or biologically active fragments thereof may also be conjugated with a detectable molecule. Preferably, the carboxyl-terminus of the TMR or GPCR is conjugated with a detectable molecule. A carboxyl-terminal tail conjugated or attached to a detectable molecule can  
10 be used in a carboxyl-terminal tail exchange to provide the detectably labeled GPCR.

00114 If the TMR or GPCR is conjugated with a detectable molecule, proximity of the TMR or GPCR with the arrestin may be readily detected. In addition, if the TMR or GPCR is conjugated with a detectable molecule,  
15 compartmentalization of the TMR or GPCR with the arrestin may be readily confirmed. The detectable molecule used to conjugate with the TMRs or GPCRs may include those as described above, including, for example, optically detectable molecules, such that they may be excited chemically, mechanically, electrically, or radioactively to emit fluorescence,  
20 phosphorescence, or bioluminescence. Preferred optically detectable molecules may be detected by immunofluorescence, luminescence, fluorescence, and phosphorescence.

00115 For example, the TMRs or GPCRs may be antibody labeled with an antibody conjugated to an immunofluorescence molecule or the TMRs or  
25 GPCRs may be conjugated with a luminescent donor. In particular, the TMRs or GPCRs may be conjugated with, for example, luciferase, for example, *Renilla* luciferase, or a rhodamine-conjugated antibody, for example, rhodamine-conjugated anti-HA mouse monoclonal antibody. Preferably, the carboxyl-terminal tail of the GPCR may be conjugated with a  
30 luminescent donor, for example, luciferase. The GPCR, preferably the carboxyl-terminal tail, also may be conjugated with GFP as described in L.

S. Barak et al. "Internal Trafficking and Surface Mobility of a Functionally Intact  $\beta_2$ -Adrenergic Receptor-Green Fluorescent Protein Conjugate", *Mol. Pharm.* (1997) 51, 177 - 184.

### **Cell Types and Substrates**

5 00116 Cells derived from different species may be useful in the present invention. Cells may be derived from rat, mouse, pig, primate, or human, for example. Cells derived from particular animals, for example higher primates, may be required to detect the reduced internalization in the methods described herein. In certain aspects of the invention, cells derived  
10 from a particular species may be useful, or preferred. In certain aspects of the invention, cells derived from mammals are useful. In certain aspects of the invention, cells derived from rat, mouse, pig, primate, or human are useful.

00117 The cells of the present invention may express at least one  
15 GPCR. The cells may further comprise a conjugate of an arrestin protein and a detectable molecule. Useful cells include eukaryotic and prokaryotic cells, including, but not limited to, bacterial cells, yeast cells, fungal cells, insect cells, nematode cells, plant cells, and animal cells. Suitable animal cells include, but are not limited to, HEK-293 cells, U2OS cells, HeLa cells,  
20 COS cells, and various primary mammalian cells. An animal model expressing a conjugate of an arrestin and a detectable molecule throughout its tissues or within a particular organ or tissue type, may also be used.

00118 The cells of the present invention may express one modified  
25 protein that results in agonist-independent localization of TMRs or GPCRs to endocytic vesicles or endosomes.

00119 A substrate may have deposited thereon a plurality of cells of the present invention. The substrate may be any suitable biologically substrate, including but not limited to, glass, plastic, ceramic, semiconductor, silica, fiber optic, diamond, biocompatible monomer, or biocompatible polymer  
30 materials.

00120 Another aspect of the invention relates to methods of treating a human or non-human subject suffering from a GPCR-related disease, such as cardiovascular disease, heart failure, asthma, nephrogenic diabetes insipidus, or hypertension. Such treatment can be performed either by  
5 administering to a subject in need of such treatment, an amount of the compounds identified by the present method sufficient to treat the GPCR-related disease, or at least to lessen the symptoms thereof.

00121 The following examples are presented in order to more fully  
10 illustrate the preferred embodiments of the invention. They should in no way be construed, however, as limiting the broad scope of the invention.

## EXAMPLES

15

### EXAMPLE 1

#### **Method of identifying a transmembrane receptor (TMR) agonist**

00122 Cells containing human or rat GPCR, and arrestin-GFP were provided. Cells were exposed to 11 test compounds and 1 control compound. The signaling was measured at 30 min, 60 min, and 120 min  
20 after exposure to the compound. Translocation was measured at 30 min, 60 min, and 120 min after exposure to the compound. GPCR internalization was quantitatively determined in the presence of each test compound, as compared to the GPCR internalization in the presence of the control compound. See for example, Fig. 4-7. The GPCR internalization was  
25 reduced in the presence of certain compounds, as compared to the control compound. It was determined that signaling was activated in the presence of certain test compounds, as compared to signaling in the absence of agonist. Signaling and translocation were measured at multiple concentrations of compound. Dose response curves for signaling and  
30 translocation were generated. These experiments demonstrated that TMRA's could be identified by this method.

00123 **Signaling measurement method**

00124 GPCR signaling was measured using AlphaScreen™ from PerkinElmer.

00125 The day before the experiment, two 125 ml spinner flasks of CHO cells were seeded at 100,000/ml in 90 ml of Ex-Cell Media (suspension media) + 10% FBS + 2 mM Glutamine + 10 mM Hepes in a 125 ml spinner flask. To spinner flask #1, Baculovirus with a pFastBac plasmid containing Human GPCR DNA was added to yield 75 viral particles per cell (75 MOI). To spinner flask #2, Baculovirus with a pFastBac plasmid containing Rat GPCR DNA was added to yield 250 viral particles per cell (250 MOI).  
10 Incubated at 37 °C overnight.

00126 The day before the experiment, two 125 ml spinner flasks of U2OS Rr#7 cells were seeded at 200,000/ml in 120 ml of Ex-Cell Media (suspension media) + 10% FBS + 2 mM Glutamine + 10 mM Hepes in a 125 ml spinner flask. To spinner flask #3, Baculovirus with a pFastBac plasmid containing Human GPCR DNA was added to yield 75 viral particles per cell (75 MOI). To spinner flask #4, Baculovirus with a pFastBac plasmid containing Rat GPCR DNA was added to yield 250 viral particles per cell (250 MOI). Incubated at 37 °C overnight.

00127 The day of the experiment: all reagents were prepared using silinized labware from frozen stocks brought to room temperature. Drug Media: EMEM supplemented with 2 mM Glutamine, 9% DMSO, 10 mM Hepes, 0.1 % BSA. Cell Media: EMEM supplemented with 500 µM IBMX. cAMP: starting cAMP concentration for addition to plate was 1 µM and was serial diluted 1:3 for 16 total concentrations. Acceptor Beads: 272 µl of 3.75 mg/ml Anti-cAMP Acceptor Beads. Donor Bead Mix: a. For U2OS Rr#7: To EMEM added 5 µM Glutamine, 0.6% Tween 20, 3.3 nM biotinylated cAMP, 6.67 nM Streptavidin Donor Beads. b. For CHO: To EMEM add 5 µM Glutamine, 0.3% Tween 20, 3.3 nM biotinylated cAMP, 6.67 nM Streptavidin Donor Beads. Compounds: compounds 1-12 were serially diluted (1:3) from a starting concentration of 1 µM in EMEM with 10 mM Hepes, 2 mM Glutamine and 0.1% BSA. Diluted compounds were  
25  
30

consolidated on a Greiner deep well 384 plate for ease of dispensing via Minitrak.

00128 Procedure: Time course of 30, 60, and 120 minutes for each of the four conditions (CHO/ Human GPCR, CHO/ Rat GPCR, U2OS Rr#7/  
5 Human GPCR, and U2OS Rr#7 Rat GPCR). 1. Labeled 13 clean 384 well Perkin Elmer Optiplates (12 plates for Compounds and 1 plate for cAMP standard curve) for each condition at 3 time points. 2. Prepared Drug Media. 3. Prepared Cell Media. 4. Prepared cAMP serial dilutions. 5. Counted cells for each of the 4 spinner flasks. 6. Centrifuged two aliquots  
10 (human GPCR and rat GPCR) of  $4.5 \times 10^6$  CHO cells and resuspended in 30 ml of Cell Media (final concentration was 150000 cells/mL). 7. Centrifuged two aliquots (human GPCR and rat GPCR) of  $12 \times 10^6$  U2OS Rr#7 cells and resuspended in 30 ml of Cell Media (final concentration was 400000 cells/mL). 8. Added 1.1  $\mu$ l of compound serial dilution curves from the 384  
15 deep well Greiner plate to dry Optiplates using the Minitrak. 9. Added 1.1  $\mu$ l of cAMP serial dilution standard curves to a dry Optiplate using a BioHit manual pipettor. All subsequent steps are light sensitive and all plates and reagents remained under green filtered light or in the dark. 10. Prepared Donor Bead Mix (made at least 30 minutes prior to use). 11. Added 65.2  $\mu$ l  
20 of 3.75 mg/ml Anti-cAMP Acceptor beads to each of the four 30 ml of cells/Cell Media. 12. Added 10.9  $\mu$ l of 3.75 mg/ml Anti-cAMP Acceptor beads to 5 ml of Cell Media. 13. Added 20  $\mu$ l/well of cells/cell media/ acceptor beads to the Compound serial dilutions using the Multidrop. 14. Added 20  $\mu$ l/well of cell media/ acceptor beads to the cAMP serial dilutions. 15. Incubated at  
25 37 °Celsius and started timers. 16. After 30 minutes, added 10  $\mu$ l/well Donor Bead Mix to the first set of four plates using the donor bead mix corresponding to the cell type. 17. After 60 minutes, added 10  $\mu$ l/well Donor Bead Mix to the second set of four plates and the cAMP standard curve control plate using the donor bead mix corresponding to the cell type. 18.  
30 After 120 minutes, manually added 10  $\mu$ l/well Donor Bead Mix to the third set of four plates using the donor bead mix corresponding to the cell type.

19. Sealed with clear adhesive TopSeal (PerkinElmer). 20. Read plates on the AlphaFusion™ (PE) 12 hrs after the assay. Left plates at room temperature in dark until read time. 21. Agonist curves were back calculated against cAMP standard curves

5 00129 **Translocation measurement method**

00130 GPCR translocation was measured using Transfluor™.

00131 The day before the experiment, six IPA washed 384 well Matrical plates were labeled according to human GPCR at 3 time points (30, 60, 120 minutes) and Rat GPCR at 3 time point (30, 60, 120 minutes). U2OS Rr#7  
10 cells (5.6e6) in 35 ml of Cell Growth Media were transduced with Human GPCR via baculovirus to achieve 75 viral particles per cell (75 MOI). U2OS Rr#7 cells (5.6e6) in 35 ml of Cell Growth Media\* were transduced with Rat GPCR via baculovirus to achieve 250 viral particles per cell (250 MOI). U2OS Rr#7/ Human GPCR cells were plated at 25 µl/well into three IPA  
15 washed, 384-well Matrical plates (4,000 cells/ well final). U2OS Rr#7/ Rat GPCR cells were plated at 25 µl/well into three IPA washed, 384-well Matrical plates (4,000 cells/ well final). Incubated at 37 °C overnight. Cell Growth Media: MEM in addition to, 10% FBS, 10 mM Hepes, 2 mM Glutamine, 10 µg/ml Gentamicin, 0.4 mg/ml G418.

20 00132 The day of the experiment: Reagent and Compound Preparation: all reagents were prepared using silinized labware from frozen stocks brought to room temperature. All values listed are final concentrations. Cell Media: EMEM supplemented with 2 mM Glutamine, 10 mM Hepes, 0.1 % BSA. Compounds: compounds 1-12 were serially diluted (1:3) from a  
25 starting concentration of 1 µM in EMEM with 10 mM Hepes, 2 mM Glutamine and 0.1% BSA. Diluted compounds were consolidated on a Greiner deep well 384 plate for ease of dispensing via Minitrak. Fix and Stain: 1 µM DRAQ5 stain and 2% Formaldehyde.

00133 Procedure: Time course of 30, 60, and 120 minutes for each of  
30 the two conditions (U2OS Rr#7 Human GPCR and U2OS Rr#7 Rat GPCR).  
1. Prepared cell media. 2. Prepared compound serial dilution curves and

consolidated in a 384 deep well Greiner plate. 3. Removed Cell growth media. 4. Added 25  $\mu$ l/well Cell Media using the Multidrop. 5. Incubated for 30 minutes at 37 °C. 6. Added 1.3  $\mu$ l of Compound serial dilutions from the 384 deep well Greiner plate to the six Matrical plates using the Minitrak. 7.  
5 Incubated at 37 °C. 8. Prepared Fix and Stain. 9. After 30 minutes, manually added 25  $\mu$ l/well Fix and Stain to the first set of two plates. 10. After 60 minutes, manually added 25  $\mu$ l/well Fix and Stain to the second set of two plates. 11. After 120 minutes, manually added 25  $\mu$ l/well Fix and Stain to the third set of two plates. 12. Sealed plates with foil, adhesive  
10 seals. 13. Read on InCell Analyzer 3000, Generation1 and analyzed for f-grains.

## EXAMPLE 2

### Method of identifying a transmembrane receptor (TMR) agonist – Morphine example

15 00134 Cells containing  $\mu$  opioid receptor, and arrestin-GFP were provided. Cells were exposed to morphine, the test compound. Cells were exposed to DAMGO, the control compound. The signaling was measured at 30 min, 60 min, and 120 min after exposure to the compound. Translocation was measured at 30 min, 60 min, and 120 min after exposure  
20 to the compound. It was then quantitatively determined that the MOR internalization was reduced in the presence of morphine, the test compound, as compared to the MOR internalization in the presence of DAMGO, the control compound. It was determined that signaling was activated in the presence of morphine, the test compound, as compared to signaling in the  
25 absence of agonist. Signaling and translocation were measured at multiple concentrations of compound. Dose response curves for signaling and translocation were generated. The results are shown in Fig. 8. These experiments demonstrated that morphine is a TMRA. While morphine is a  
30 TMRA, it may be derivitized to form a compound which further reduces MOR internalization.

00135 **Signaling measurement method**

00136  $\mu$  opioid receptor signaling was measured using AlphaScreen™ from PerkinElmer.

00137 The day before the experiment, CHO cells were seeded at 100,000/ml in 70 ml of Ex-Cell Media (suspension media) + 10% FBS + 2 mM Glutamine + 10 mM Hepes in a 125 ml spinner flask; 4.2 ml (1e9 stock) baculovirus was added at seeding thus yielding 600 viral particles per cell (600MOI). Incubated at 37 °C overnight.

00138 The day of the experiment: all reagents were made up fresh on the day of the assay unless noted otherwise. Agonists were from frozen stocks. Buffer: EMEM (SFM) in addition to 10 mM Hepes, 2 mM Glutamine. Drug Media: 4.5 ml 100% DMSO; 45.5 ml EMEM (SFM) in addition to 10 mM Hepes, 2 mM Glutamine (1:11 dilution); (1% = 1 g / 100 ml) 0.5 g BSA; Yields 10% DMSO, 1% BSA working concentration. Cell Media: 35 ml EMEM (SFM) in addition to 10 mM Hepes, 2 mM Glutamine; Add 35  $\mu$ l (500  $\mu$ M) IBMX (1:1000 dilution). Forskolin Media: 1  $\mu$ l (1 mM) forskolin into 62.7  $\mu$ l EMEM (SFM) in addition to 10 mM Hepes, 2 mM Glutamine (1:63.7 dilution). Yields 1.57e-3 working concentration. 36  $\mu$ l (1.57e-3M forskolin) into 17.96 ml EMEM (SFM) in addition to 10 mM Hepes, 2 mM Glutamine (1:500 dilution); Yields 3.15e-6M working concentration. DAMGO: 2  $\mu$ l (10 mM) DAMGO into 93.2  $\mu$ l Drug Media (1:47.6 dilution); Yields 2.1e-4M working concentration. 2.1e-4 M high concentration DAMGO (1:3) serial dilutions, 16 pts; 40  $\mu$ l into 80  $\mu$ l Drug media (using silinized tips and tip changes between dilutions). Morphine: 2  $\mu$ l (10 mM) morphine into 93.2  $\mu$ l Drug Media (1:47.6 dilution); Yields 2.1e-4M working concentration. 2.1e-4 M high concentration DAMGO (1:3) serial dilutions, 16 pts; 40  $\mu$ l into 80  $\mu$ l Drug media (using silinized tips and tip changes between dilutions). cAMP: 1  $\mu$ l 5mM cAMP into 179.7  $\mu$ l Drug Media (1:180.7 dilution); Yields 2.8e-5 M working cAMP concentration. 2.8e-5 M high concentration cAMP (1:3) serial dilutions, 16 pts; 40  $\mu$ l into 80  $\mu$ l Drug media (using silinized tips and tip changes between dilutions). Acceptor Beads: 71.76  $\mu$ l (3.75 mg/ml) beads added to 26 ml cells + cell media (1:362.3) dilution. 11  $\mu$ l (3.75 mg/ml)

beads added to 4 ml cell media (for cAMP wells). Donor Beads: (1:8) 2 ml 10% Tween-20; (1:730) 29  $\mu$ l (10  $\mu$ M) Biotinylated-cAMP; (1:180.5) 88.6  $\mu$ l (5 mg/ml) donor beads; 13.89 ml EMEM (SFM) in addition to 10 mM Hepes, 2 mM Glutamine.

5 00139 Procedure: 1. Made drug media. 2. Made cell media (thoroughly vortex IBMX into solution). 3. Made DAMGO, morphine and cAMP serial dilutions in drug media (using a Biohit pipette). 4. Added 10  $\mu$ l of each concentration into designated wells of a silinized, 384-well Remp polypropylene plate. 5. Added 10  $\mu$ l of buffer (drug media) to basal wells  
10 and wells that will receive only a maximum concentration of forskolin. (stock plate). 6. Aspirated appropriate volume from the stock plate and transferred 1.5  $\mu$ l of drug/buffer into each of three Optiplates (PE) using a Minitrack instrument (PE). 7. Counted cells from spinner flask. Pelleted cells and resuspended in 26 ml of cell media (26 ml is enough volume for 3 x 384  
15 plate). Final cell concentration was 6,000 cells per 20  $\mu$ l. 8. Placed 4 ml of cell media in a separate tube (no cells). This was used for the cAMP serial dilutions. 9. All subsequent steps are light sensitive and all plates and reagents remained under green filtered light or in the dark. 10. Added 71.76  $\mu$ l of acceptor beads to the resuspended cells and mixed gently. 11. Added  
20 11  $\mu$ l of acceptor beads to the cell media (containing no cells) and mixed. 12. Using a multidrop, dispensed 20  $\mu$ l of cells + acceptor to all wells except cAMP wells. 13. Added 20  $\mu$ l of plain cell media + acceptor to cAMP wells, using a BioHit pipette. 14. Tapped plates gently to mix. 15. Incubated plate for 30 min at room temperature. 16. During incubation, made forskolin  
25 media. 17. After 30 min, added 10  $\mu$ l of the working concentration of forskolin to all wells except for the basal and cAMP wells using a multidrop instrument. 18. Added 10  $\mu$ l to basal and cAMP wells using a multidrop instrument. 19. Tapped plates gently to mix. 20. Incubated plate at 37 °C  
30 21. Started timers. (Times set for 30 min, 60 min and 120 min). 22. Made donor bead media and incubated at room temperature in a drawer (complete darkness). This was incubated for at least 30 min before it was

added to the first assay plate. 23. Dispensed 10  $\mu$ l of donor mix to the entire assay plate using a multidrop instrument when each plate's time was up.

24. Tapped plates gently to mix. 25. Sealed with clear adhesive TopSeal (PerkinElmer). 26. Read plates on the AlphaFusion™ (PE) 12 hrs after the

5 assay. Left plates at room temp in dark until read time. 27. Curves were fit using MDL's LSW data analysis wizard. 28. Agonist curves were back calculated against cAMP standard curves.

00140 Final Concentrations: DAMGO: Serial dilutions started at 1e-5M (1:3 16pts), Morphine: Serial dilutions started at 1e-5M (1:3 16pts), cAMP:

10 Serial dilutions started at 1e-6M (1:3 16pts), Acceptor: 5  $\mu$ g/ml, Forskolin: 1e-6M, Donor: 0.3% Tween-20; 3.3 nM Biotinylated-cAMP; 6.67  $\mu$ g/ml donor beads, Cells: 6,000/20  $\mu$ l, DMSO: 0.36%, BSA: 0.036%

00141 **Translocation measurement method**

00142  $\mu$  opioid receptor (MOR) translocation was measured using  
15 Transfluor™.

00143 The day before the experiment, U2OS-GFP-MOR stable cell line, containing MOR and arrestin-GFP, was plated in each of 3 IPA washed, 384-well Matrical plates at 5,000 cells/25  $\mu$ l. Growing media: MEM in addition to, 10% FBS, 10 mM Hepes, 2 mM Glutamine. Incubate at 37 °C

20 overnight.

00144 The day of assay: Reagents Prep and dilutions. All reagents were made up fresh on the day of the assay unless noted otherwise. Agonists were from frozen stocks. All dilutions were performed with silinized tips and tip changes between dilutions. 1. Diluted DAMGO: 20  $\mu$ l (1e-2) stock

25 DAMGO into 180  $\mu$ l of EMEM (SFM) in addition to 10 mM Hepes, 10% DMSO (1:100 dilution), 1% BSA (1 g/100 ml). Yields: 1e-3M DAMGO working concentration. Serial dilutions (1:3) of the 1e-3M working stock (16pts) in a 96-well polypropylene, silinized plate (40  $\mu$ l into 80  $\mu$ l). 2.

30 Diluted Morphine: 20  $\mu$ l (1e-2) stock morphine into 180  $\mu$ l of EMEM (SFM) in addition to 10 mM Hepes, 10% DMSO (1:100 dilution), 1% BSA (1 g/100 ml). Yields: 1e-3M morphine working concentration. Serial dilutions (1:3) of the

1e-3M working stock (16 pts) in a 96-well polypropylene, silinized plate (40  
µl into 80 µl). 3. Added 2 µl of serial dilutions into designated wells of a  
silinized, polypropylene, Remp 384-well plate. 4. Added 2 µl of buffer  
EMEM (SFM) in addition to 10 mM Hepes, 10% DMSO, 1% BSA to basal  
5 wells. 5. Added 2 µl of high concentration from the serial dilutions to a block  
of wells (max agonist) to use in order to calculate statistics. 6. Using a  
multidrop, dispensed 15 µl buffer EMEM (SFM) in addition to 10 mM Hepes,  
10% DMSO, 1% BSA to the entire plate containing the 2 µl. This brought the  
serial dilution, high concentration to 1.18e-4 M. 7. Tapped plate to mix. 8.  
10 Removed the 25 µl of growing media from cells and replaced with 23 µl  
EMEM (SFM) in addition to 10 mM Hepes. (Minitrack instrument (PE)). 9.  
Aspirated 2 µl from the diluted drug plate and stamped onto the 23 µl in the  
assay plate. (Minitrack instrument (PE)). 10. Mixed using a 10 µl aspirate  
and dispense step. (Minitrack instrument (PE)). 11. Started timers. (Times  
15 were set for 30 min for plate1, 60 min for plate2 and 120 min for plate3) 12.  
Added 25 µl of 4% formaldehyde + 2 µM DRAQ5 nuclear dye to each assay  
plate when time has expired for each plate. (Final concentrations: 2%  
formaldehyde, 1 µM DRAQ5). 13. Sealed plates with foil, adhesive seals.  
14. Read on InCell Analyzer 3000, Generation1 and analyzed for f-grains.  
20 15. Curves were fit from MDL's LSW data analysis wizard.

00145 While the invention has been described and illustrated herein by  
references to various specific material, procedures and examples, it is  
understood that the invention is not restricted to the particular material  
25 combinations of material, and procedures selected for that purpose.  
Numerous variations of such details can be implied as will be appreciated by  
those skilled in the art.

30

00146 The following is a list of documents related to the above disclosure and particularly to the experimental procedures and discussions. The following documents, as well as any documents referenced in the  
5 foregoing text, should be considered as incorporated by reference in their entirety.

- Attramadal, H. , Arriza, J. L. , Aoki, C. , Dawson, T. M. , Codina, J. , Kwatra, M. M. , Snyder, S. H. , Caron, M. G. & Lefkowitz, R. J. (1992) *J. Biol. Chem.*  
10 267, 17882-17890
- Barak, L. S., Oakley, R. H., Laporte, S. A. and Caron, M. G. (2001) *Proc. Natl. Acad. Sci. USA* 98, 93-98
- Barak, L. S. , Warabi, K. , Feng, X. , Caron, M. G. & Kwatra, M. M. (1999) *J. Biol. Chem.* 274, 7565-7569
- 15 Barak, L. S. , Ferguson, S. S. , Zhang, J. & Caron, M. G. (1997) *J. Biol. Chem.* 272, 27497-27500
- Barak, L. S. , Ferguson, S. S. , Zhang, J. , Martenson, C. , Meyer, T. & Caron, M. G. (1997) *Mol. Pharmacol.* 51, 177-184
- Barak, L. S. , Menard, L. , Ferguson, S. S. , Colapietro, A. M. & Caron, M. G.  
20 (1995) *Biochemistry* 34, 15407-15414
- Ferguson, S. S. , Barak, L. S. , Zhang, J. & Caron, M. G. (1996) *Can. J. Physiol. Pharmacol.* 74, 1095-1110
- Ferguson, S. S. , Menard, L. , Barak, L. S. , Koch, W. J. , Colapietro, A. M. & Caron, M. G. (1995) *J. Biol. Chem.* 270, 24782-24789
- 25 Inglese, J., Koch, W.J., Caron, M.G., Lefkowitz, R.J. (1992) *Nature* 359:147-150
- Kim, K.-M., Valenzano, K. J., Robinson, S. R., Yao, W. D., Barak, L. S., Caron, M. G. (2001) *J. Biol. Chem.* 276: 37409-37414
- Laporte, S. A. , Oakley, R. H. , Holt, J. A. , Barak, L. S. & Caron, M. G.  
30 (2000) *J. Biol. Chem.* 275, 23120-23126
- Laporte, S. A. , Oakley, R. H. , Zhang, J. , Holt, J. A. , Ferguson, S. S. ,

- Caron, M. G. & Barak, L. S. (1999) Proc. Natl. Acad. Sci. USA 96, 3712-3717
- Menard, L. , Ferguson, S. S. , Zhang, J. , Lin, F. T. , Lefkowitz, R. J. , Caron, M. G. & Barak, L. S. (1997) Mol. Pharmacol. 51, 800-808
- 5 Mhaouty-Kodja, S. , Barak, L. S. , Scheer, A. , Abuin, L. , Diviani, D. , Caron, M. G. & Cotecchia, S. (1999) Mol. Pharmacol. 55, 339-347
- Oakley, R. H., Laporte, S. A., Holt, J. A., Barak, L. S., Caron, M. G. (2001). J. Biol. Chem. 276: 19452-19460
- Oakley, R. H. , Laporte, S. A. , Holt, J. A. , Caron, M. G. & Barak, L. S. (2000) J. Biol. Chem. 275, 17201-17210
- 10 Oakley, R. H. , Laporte, S. A. , Holt, J. A. , Barak, L. S. & Caron, M. G. (1999) J. Biol. Chem. 274, 32248-32257
- Zhang, J. , Barak, L. S. , Anborgh, P. H. , Laporte, S. A. , Caron, M. G. & Ferguson, S. S. (1999) J. Biol. Chem. 274, 10999-11006
- 15 Zhang, J. , Barak, L. S. , Winkler, K. E. , Caron, M. G. & Ferguson, S. S. (1997) J. Biol. Chem. 272, 27005-27014

20

## CLAIMS

1. A method of identifying a transmembrane receptor (TMR) agonist, wherein the TMR agonist (TMRA) is capable of activating TMR signaling while exhibiting reduced TMR internalization over a control compound, comprising the steps of:
- (a) providing a cell comprising at least one TMR, or a biologically active fragment thereof, wherein the cell further comprises arrestin, or a biologically active fragment thereof,
  - (b) exposing the cell to at least one test compound,
  - (c) measuring the signaling at two or more points in time,
  - (d) measuring the translocation of the TMR at two or more points in time, and
  - (e) quantitatively determining if the internalization is reduced by comparing the TMR internalization in the presence of the test compound to the TMR internalization in the presence of a control compound, and wherein the signaling is activated as compared to TMR signaling in the absence of agonist.
2. The method of claim 1, wherein the TMR is a GPCR.
3. The method of claim 1, wherein the translocation of the TMR is measured by monitoring localization of a detectable molecule bound to the arrestin or the TMR.
4. The method of claim 1, wherein signaling is quantitated by measuring an intracellular effector, wherein said effector may be cAMP, cyclic GMP, Calcium, a lipid, phosphatidylinositol, a hydrogen ion, or an ion transport molecule.

5. The method of claim 1, wherein the control compound is a natural ligand or natural agonist.
6. The method of claim 1, wherein the test compound is a modified  
5 natural ligand or modified natural agonist.
7. The method of claim 1, wherein the test compound is a known pharmaceutically relevant compound, or is derived from a known pharmaceutically relevant compound.  
10
8. The method of claim 1, wherein the signaling is activated for a longer time period after stimulation by the TMRA than the length of time of activation after stimulation by the control compound.
- 15 9. The method of claim 1, wherein the translocation of the TMR is measured by determining the localization in the plasma membrane, pits, endosomes, endocytic vesicles, or cytosol.
10. The method of claim 2, wherein the GPCR is a class A, or class B  
20 receptor.
11. The method of claim 2, wherein the GPCR is a  $\mu$  opioid,  $\beta_1$ AR,  $\beta_2$ AR, or dopamine receptor.
- 25 12. The method of claim 1, wherein the translocation of the TMR is measured by visualization of a radioisotope, an epitope tag, an affinity label, an enzyme, a fluorescent group, or a chemiluminescent group attached to the arrestin or the TMR.
- 30 13. The method of claim 1, wherein the signaling is measured at the

same time as the translocation is measured.

14. The method of claim 1, wherein the cell is exposed to the compound once, and wherein the cell is not exposed a second time to the compound.

5

15. A compound discovered by the method of claim 1.

16. The method of claim 1, wherein the TMR is a rat, human, mouse, pig, or primate TMR.

10

17. The method of claim 1, wherein the method is repeated, and wherein the TMR in the repeat method is from a different species than in the original method.

15 18. The method of claim 17, wherein a test compound that is a TMRA in the original method is not a TMRA in the repeat method, and wherein the repeat method contains a TMR from a different species.

20 19. The method of claim 1, wherein the test compound is from a combinatorial library.

20. The method of claim 1, wherein the signaling in the presence of the test compound is approximately equal to or greater than the signaling in the presence of the control compound.

25

21. The method of claim 1, wherein the method is repeated at different concentrations of compound to yield a dose response curve for the signaling measurement and a dose response curve for the translocation measurement in the presence of the test compound.

30

22. The method of claim 21, wherein the quantitative determination includes a comparison of the dose response curve for the signaling measurement to the dose response curve for the translocation measurement.

5

23. The method of claim 21, wherein a second dose response curve for the signaling measurement and a second dose response curve for the translocation measurement are determined in the presence of control compound.

10

24. The method of claim 23, wherein dose response curve for the translocation measurement in the presence of the test compound is reduced as compared to the dose response curve for the translocation measurement in the presence of the control compound.

15

25. The method of claim 23, wherein the dose response curve for the signaling measurement in the presence of the test compound is approximately equal to or greater than the dose response curve for the signaling measurement in the presence of the control compound.

20

26. The method of claim 24, wherein the reduced translocation is determined by a decrease in the Max of the dose response curve for the translocation measurement in the presence of the test compound, as compared to the Max of the dose response curve for the translocation measurement in the presence of the control compound.

25

27. The method of claim 24, wherein the reduced translocation is determined by an increase in the EC50 of the dose response curve for the translocation measurement in the presence of the test compound, as compared to the EC50 of the dose response curve for the translocation

30

measurement in the presence of the control compound.

28. A method of identifying a modified TMR agonist, wherein the modified TMR is capable of activating TMR signaling while exhibiting reduced TMR internalization over an unmodified compound, comprising the steps of:
- (a) providing an agonist or ligand of a TMR,
  - (b) modifying the agonist or ligand,
  - (c) providing a cell comprising at least one TMR, or a biologically active fragment thereof, wherein the cell further comprises arrestin, or a biologically active fragment thereof,
  - (d) exposing the cell to a modified agonist(s) or modified ligand(s),
  - (e) measuring the signaling at two or more points in time,
  - (f) measuring the translocation of the TMR at two or more points in time, and
  - (g) quantitatively determining if the internalization is reduced by comparing the TMR internalization in the presence of the test compound to the TMR internalization in the presence of an unmodified compound, and wherein the signaling is activated as compared to TMR signaling in the absence of agonist.
29. The method of claim 28, wherein the TMR is a GPCR.
30. The method of claim 28, wherein the translocation of the TMR is measured by monitoring localization of a detectable molecule bound to the arrestin or the TMR.
31. The method of claim 28, wherein signaling is quantitated by measuring an intracellular effector, wherein said effector may be cAMP, cyclic GMP, Calcium, a lipid, phosphatidylinositol, a hydrogen ion, or an ion transport molecule.

32. The method of claim 28, wherein the control compound is a natural ligand or natural agonist.
- 5 33. The method of claim 32, wherein the natural ligand or natural agonist is a known pharmaceutically relevant compound, or is derived from a known pharmaceutically relevant compound.
34. A compound discovered by the method of claim 28.
- 10 35. The method of claim 28, wherein the signaling is activated for a longer time period after stimulation by the TMRA than the length of time of activation after stimulation by the control compound.
- 15 36. The method of claim 28, wherein the translocation of the TMR is measured by determining the localization in the plasma membrane, pits, endosomes, endocytic vesicles, or cytosol.
- 20 37. The method of claim 29, wherein the GPCR is a class A, or class B receptor.
38. The method of claim 29, wherein the GPCR is a  $\mu$  opioid,  $\beta_1$ AR,  $\beta_2$ AR, or dopamine receptor.
- 25 39. The method of claim 30, wherein the translocation of the TMR is measured by visualization of a radioisotope, an epitope tag, an affinity label, an enzyme, a fluorescent group, or a chemiluminescent group attached to the arrestin or the TMR.
- 30 40. The method of claim 28, wherein the signaling is measured at the

same time as the translocation is measured.

41. The method of claim 28, wherein the cell is exposed to the compound once, and wherein the cell is not exposed a second time to the compound.

5

42. A compound discovered by the method of claim 28.

43. The method of claim 28, wherein the TMR is a rat, human, mouse, pig, or primate TMR.

10

44. The method of claim 28, wherein the method is repeated, and wherein the TMR in the repeat method is from a different species than in the original method.

15

45. The method of claim 44, wherein a test compound that is a TMRA in the original method is not a TMRA in the repeat method, and wherein the repeat method contains a TMR from a different species.

20

46. The method of claim 28, wherein the test compound is from a combinatorial library.

47. The method of claim 28, wherein the signaling in the presence of the test compound is approximately equal to or greater than the signaling in the presence of the control compound.

25

48. The method of claim 28, wherein the method is repeated at different concentrations of compound to yield a dose response curve for the signaling measurement and a dose response curve for the translocation measurement in the presence of the test compound.

30

49. The method of claim 48, wherein the quantitative determination includes a comparison of the dose response curve for the signaling measurement to the dose response curve for the translocation measurement.
- 5
50. The method of claim 48, wherein a second dose response curve for the signaling measurement and a second dose response curve for the translocation measurement are determined in the presence of control compound.
- 10
51. The method of claim 50, wherein dose response curve for the translocation measurement in the presence of the test compound is reduced as compared to the dose response curve for the translocation measurement in the presence of the control compound.
- 15
52. The method of claim 50, wherein the dose response curve for the signaling measurement in the presence of the test compound is approximately equal to or greater than the dose response curve for the signaling measurement in the presence of the control compound.
- 20
53. The method of claim 51, wherein the reduced translocation is determined by a decrease in the Max of the dose response curve for the translocation measurement in the presence of the test compound, as compared to the Max of the dose response curve for the translocation measurement in the presence of the control compound.
- 25
54. The method of claim 51, wherein the reduced translocation is determined by an increase in the EC50 of the dose response curve for the translocation measurement in the presence of the test compound, as compared to the EC50 of the dose response curve for the translocation
- 30

measurement in the presence of the control compound.

55. A method of identifying a transmembrane receptor (TMR) agonist, wherein the TMR agonist (TMRA) is capable of activating TMR signaling while exhibiting reduced TMR internalization over a control compound, comprising the steps of:
- (a) providing a cell comprising at least one TMR, or a biologically active fragment thereof, wherein the cell further comprises arrestin, or a biologically active fragment thereof,
  - (b) exposing the cell to at least one test compound,
  - (c) measuring the signaling at one or more concentration of compound,
  - (d) measuring the translocation of the TMR at one or more concentration of compound, and
  - (e) quantitatively determining if the internalization is reduced by comparing the TMR internalization in the presence of the test compound to the TMR internalization in the presence of a control compound, and wherein the signaling is activated as compared to TMR signaling in the absence of agonist.

20

56. The method of claim 55, wherein the TMR is a GPCR.

57. The method of claim 55, wherein the translocation of the TMR is measured by monitoring localization of a detectable molecule bound to the arrestin or the TMR.

25

58. The method of claim 55, wherein signaling is quantitated by measuring an intracellular effector, wherein said effector may be cAMP, cyclic GMP, Calcium, a lipid, phosphatidylinositol, a hydrogen ion, or an ion transport molecule.

30

59. The method of claim 55, wherein the control compound is a natural ligand or natural agonist.

5 60. The method of claim 55, wherein the test compound is a modified natural ligand or modified natural agonist.

61. The method of claim 55, wherein the test compound is a known pharmaceutically relevant compound, or is derived from a known  
10 pharmaceutically relevant compound.

62. The method of claim 55, wherein the signaling is activated for a longer time period after stimulation by the TMRA than the length of time of activation after stimulation by the control compound.

15

63. The method of claim 55, wherein the translocation of the TMR is measured by determining the localization in the plasma membrane, pits, endosomes, endocytic vesicles, or cytosol.

20 64. The method of claim 56, wherein the GPCR is a class A, or class B receptor.

65. The method of claim 56, wherein the GPCR is a  $\mu$  opioid,  $\beta_1$ AR,  $\beta_2$ AR, or dopamine receptor.

25

66. The method of claim 55, wherein the translocation of the TMR is measured by visualization of a radioisotope, an epitope tag, an affinity label, an enzyme, a fluorescent group, or a chemiluminescent group attached to the arrestin or the TMR.

30

67. The method of claim 55, wherein the signaling is measured at the same time as the translocation is measured.
68. The method of claim 55, wherein the cell is exposed to the compound once, and wherein the cell is not exposed a second time to the compound.  
5
69. A compound discovered by the method of claim 55.
70. The method of claim 55, wherein the TMR is a rat, human, mouse, pig, or primate TMR.  
10
71. The method of claim 55, wherein the method is repeated, and wherein the TMR in the repeat method is from a different species than in the original method.  
15
72. The method of claim 71, wherein a test compound that is a TMRA in the original method is not a TMRA in the repeat method, and wherein the repeat method contains a TMR from a different species.
73. The method of claim 55, wherein the test compound is from a combinatorial library.  
20
74. The method of claim 55, wherein the signaling in the presence of the test compound is approximately equal to or greater than the signaling in the presence of the control compound.  
25
75. The method of claim 55, wherein the method is repeated at different concentrations of compound to yield a dose response curve for the signaling measurement and a dose response curve for the translocation measurement in the presence of the test compound.  
30

76. The method of claim 75, wherein the quantitative determination includes a comparison of the dose response curve for the signaling measurement to the dose response curve for the translocation measurement.  
5
77. The method of claim 75, wherein a second dose response curve for the signaling measurement and a second dose response curve for the translocation measurement are determined in the presence of control compound.  
10
78. The method of claim 77, wherein dose response curve for the translocation measurement in the presence of the test compound is reduced as compared to the dose response curve for the translocation measurement in the presence of the control compound.  
15
79. The method of claim 77, wherein the dose response curve for the signaling measurement in the presence of the test compound is approximately equal to or greater than the dose response curve for the signaling measurement in the presence of the control compound.  
20
80. The method of claim 78, wherein the reduced translocation is determined by a decrease in the Max of the dose response curve for the translocation measurement in the presence of the test compound, as compared to the Max of the dose response curve for the translocation measurement in the presence of the control compound.  
25
81. The method of claim 78, wherein the reduced translocation is determined by an increase in the EC50 of the dose response curve for the translocation measurement in the presence of the test compound, as  
30

compared to the EC50 of the dose response curve for the translocation measurement in the presence of the control compound.

82. A method of identifying a modified TMR agonist, wherein the modified  
5 TMRA is capable of activating TMR signaling while exhibiting reduced TMR  
internalization over an unmodified compound, comprising the steps of:
- (a) providing an agonist or ligand of a TMR,
  - (b) modifying the agonist or ligand,
  - (c) providing a cell comprising at least one TMR, or a biologically  
10 active fragment thereof, wherein the cell further comprises arrestin, or a  
biologically active fragment thereof,
  - (d) exposing the cell to a modified agonist(s) or modified ligand(s),
  - (e) measuring the signaling at two or more concentrations of  
compound,
  - 15 (f) measuring the translocation of the TMR at two or more  
concentrations of compound, and
  - (g) quantitatively determining if the internalization is reduced by  
comparing the TMR internalization in the presence of the test compound to  
the TMR internalization in the presence of an unmodified compound, and  
20 wherein the signaling is activated as compared to TMR signaling in the  
absence of agonist.

83. The method of claim 82, wherein the TMR is a GPCR.

25 84. The method of claim 82, wherein the translocation of the TMR is  
measured by monitoring localization of a detectable molecule bound to the  
arrestin or the TMR.

85. The method of claim 82, wherein signaling is quantitated by  
30 measuring an intracellular effector, wherein said effector may be cAMP,

cyclic GMP, Calcium, a lipid, phosphatidylinositol, a hydrogen ion, or an ion transport molecule.

86. The method of claim 82, wherein the control compound is a natural  
5 ligand or natural agonist.

87. The method of claim 86, wherein the natural ligand or natural agonist is a known pharmaceutically relevant compound, or is derived from a known pharmaceutically relevant compound.  
10

88. A compound discovered by the method of claim 82.

89. The method of claim 82, wherein the signaling is activated for a longer time period after stimulation by the TMRA than the length of time of  
15 activation after stimulation by the control compound.

90. The method of claim 82, wherein the translocation of the TMR is measured by determining the localization in the plasma membrane, pits, endosomes, endocytic vesicles, or cytosol.  
20

91. The method of claim 83, wherein the GPCR is a class A, or class B receptor.

92. The method of claim 83, wherein the GPCR is a  $\mu$  opioid,  $\beta_1$ AR,  $\beta_2$ AR, or dopamine receptor.  
25

93. The method of claim 84, wherein the translocation of the TMR is measured by visualization of a radioisotope, an epitope tag, an affinity label, an enzyme, a fluorescent group, or a chemiluminescent group attached to  
30 the arrestin or the TMR.

94. The method of claim 82, wherein the signaling is measured at the same time as the translocation is measured.
- 5 95. The method of claim 82, wherein the cell is exposed to the compound once, and wherein the cell is not exposed a second time to the compound.
96. A compound discovered by the method of claim 82.
- 10 97. The method of claim 82, wherein the TMR is a rat, human, mouse, pig, or primate TMR.
98. The method of claim 82, wherein the method is repeated, and wherein the TMR in the repeat method is from a different species than in the  
15 original method.
99. The method of claim 98, wherein a test compound that is a TMRA in the original method is not a TMRA in the repeat method, and wherein the repeat method contains a TMR from a different species.  
20
100. The method of claim 82, wherein the test compound is from a combinatorial library.
101. The method of claim 82, wherein the signaling in the presence of the  
25 test compound is approximately equal to or greater than the signaling in the presence of the control compound.
102. The method of claim 82, wherein the method is repeated at different concentrations of compound to yield a dose response curve for the signaling  
30 measurement and a dose response curve for the translocation

measurement in the presence of the test compound.

103. The method of claim 102, wherein the quantitative determination includes a comparison of the dose response curve for the signaling  
5 measurement to the dose response curve for the translocation measurement.

104. The method of claim 102, wherein a second dose response curve for the signaling measurement and a second dose response curve for the  
10 translocation measurement are determined in the presence of control compound.

105. The method of claim 104, wherein dose response curve for the translocation measurement in the presence of the test compound is reduced  
15 as compared to the dose response curve for the translocation measurement in the presence of the control compound.

106. The method of claim 104, wherein the dose response curve for the signaling measurement in the presence of the test compound is  
20 approximately equal to or greater than the dose response curve for the signaling measurement in the presence of the control compound.

107. The method of claim 105, wherein the reduced translocation is determined by a decrease in the Max of the dose response curve for the  
25 translocation measurement in the presence of the test compound, as compared to the Max of the dose response curve for the translocation measurement in the presence of the control compound.

108. The method of claim 105, wherein the reduced translocation is  
30 determined by an increase in the EC50 of the dose response curve for the

translocation measurement in the presence of the test compound, as compared to the EC50 of the dose response curve for the translocation measurement in the presence of the control compound.

5

**FIGURE 1**

Human G Protein Coupled Receptor Family  
(Receptors known as of January, 1999)

CLASS	LIGAND	NUMBER	TISSUE	PHYSIOLOGY	THERAPEUTICS
•Class I Rhodopsin like					
	•Amine				
	•Acetylcholine (muscarinic & nicotinic)	5	Brain, Nerves, Heart	Neurotransmitter	Acuity, Alzheimer's
	•Adrenoceptors				
	•Alpha Adrenoceptors	6	Brain, Kidney, Lung	Gluconeogenesis	Diabetes, Cardiovascular
	•Beta Adrenoceptors	3	Kidney, Heart	Muscle Contraction	Cardiovascular, Respiratory
	•Dopamine	5	Brain, Kidney, GI	Neurotransmitter	Cardiovascular, Parkinson's
	•Histamine	2	Vascular, Heart, Brain	Vascular Permeability	Anti-inflammatory, Ulcers
	•Serotonin (5-HT)	16	Most Tissues	Neurotransmitter	Depression, Insomnia, Analgesic
	•Peptide				
	•Angiotensin	2	Vascular, Liver, Kidney	Vasoconstriction	Cardiovascular, Endocrine
	•Bradykinin	1	Liver, Blood	Vasodilation,	Anti-inflammatory, Asthma
	•C5a anaphylatoxin	1	Blood	Immune System	Anti-inflammatory
	•Fmet-leu-phe	3	Blood	Chemoattractant	Anti-inflammatory
	•Interleukin-8	1	Blood	Chemoattractant	Anti-inflammatory
	•Chemokine	6	Blood	Chemoattractant	Anti-inflammatory
	•Orexin	2	Brain	Fat Metabolism	Obesity
	•Nociceptin	1	Brain	Bronchodilator, Pain	Airway Diseases, Anesthetic
	•CCK (Gastrin)	2	Gastrointestinal	Motility, Fat Absorption	Gastrointestinal, Obesity, Parkinson's
	•Endothelin	2	Heart, Bronchus, Brain	Muscle Contraction	Cardiovascular, Respiratory
	•Melanocortin	5	Kidney, Brain	Metabolic Regulation	Anti-inflammatory, Analgesics
	•Neuropeptide Y	5	Nerves, Intestine, Blood	Neurotransmitter	Behavior, Memory, Cardiovascular
	•Neurotensin	1	Brain,	CNS	Cardiovascular, Analgesic
	•Opioid	3	Brain,	CNS	Depression, Analgesic
	•Somatostatin	5	Brain, Gastrointestinal	Neurotransmitter	Oncology, Alzheimer's

Figure 1, pg. 1 of 3

·Tachykinin (Substance P, NK <sub>A1</sub> )	3	Brain Nerves	Neurohormone	Depression, Analgesic
·Thrombin	3	Platelets, Blood Vessels	Coagulation	Anti-coagulant, Anti-inflammatory
·Vasopressin-like	4	Arteries, Heart, Bladder	Water Balance	Anti-diuretic, Diabetic Complications
·Galinin	1	Brain, Pancreas	Neurotransmitter	Analgesics, Alzheimer's
·Hormone protein				
·Follicle stimulating hormone	1	Ovary, Testis	Endocrine	Infertility
·Lutropin-choriogonadotropic	1	Ovary, Testis	Endocrine	Infertility
·Thyrotropin	1	Thyroid	Endocrine	Thyroidism, Metabolism
·(Rhod)opsin				
·Opsin	5	Eye	Photoreception	Ophthalmic Diseases
·Olfactory	4(~1000)	Nose	Smell	Olfactory Diseases
·Prostanoid				
·Prostaglandin	5	Arterial, Gastrointestinal	Vasodilation, Pain	Cardiovascular, Analgesic
·Lysophosphatidic Acid	2	Vessels, Heart, Lung	Inflammation	Cancer, Anti-inflammatory
·Sphingosine-1-phosphate	2	Most Cells	Cell proliferation	Cancer
·Leukotriene	1	White Blood Cells, Bronchus	Inflammation	Asthma, Rheumatoid Arthritis
·Prostacyclin	1	Arterial, Gastrointestinal	Platelet Regulation	Cardiovascular
·Thromboxane	1	Arterial, Bronchus	Vasoconstriction	Cardiovascular, Respiratory
·Nucleotide-like				
·Adenosine	4	Vascular, Bronchus	Multiple Effects	Cardiovascular, Respiratory
·Purinoceptors	4	Vascular, Platelets	Relaxes Muscle	Cardiovascular, Respiratory
·Cannabis	2	Brain	Sensory Perception	Analgesics, Memory
·Platelet activating factor	1	Most Peripheral Tissues	Inflammation	Anti-inflammatory, Anti-asthmatic
·Gonadotropin-releasing hormone like				
·Gonadotropin-releasing hormone	1	Reproductive Organs, Pituitary	Reproduction	Prostate Cancer, Endometriosis
·Thyrotropin-releasing hormone	1	Pituitary, Brain	Thyroid Regulation	Metabolic Regulation
·Growth hormone-inhibiting factor	1	Gastrointestinal	Neuroendocrine	Oncology, Alzheimer's
·Melatonin	1	Brain, Eye, Pituitary	Neuroendocrine	Regulation of Circadian Cycle

Figure 1, pg. 2 of 3

**•Class II**  
Secretin like

•Secretin	1	Gastrointestinal, Heart	Digestion	Obesity, Gastrointestinal
•Calcitonin	1	Bone, Brain	Calcium Resorption	Osteoporosis
•Corticotropin releasing factor/urocortin	1	Adrenal, Vascular, Brain	Neuroendocrine	Stress, Mood, Obesity
•Gastric inhibitory peptide (GIP)	1	Adrenals, Fat Cells	Sugar/Fat Metabolism	Diabetes, Obesity
•Glucagon	1	Liver, Fat Cells, Heart	Gluconeogenesis	Cardiovascular
•Glucagon-like Peptide 1 (GLP-1)	1	Pancreas, Stomach, Lung	Gluconeogenesis	Cardiovascular, Diabetes, Obesity
•Growth hormone-releasing hormone	1	1	Brain	Neuroendocrine Growth Regulation
•Parathyroid hormone	1	Bone, Kidney	Calcium Regulation	Osteoporosis
•PACAP	1	Brain, Pancreas, Adrenals	Metabolism	Metabolic Regulation
•Vasoactive intestinal polypeptide (VIP)	1	Gastrointestinal	Motility	Gastrointestinal

**•Class III**

•Metabotropic Glutamate	7	Brain	Sensory Perception	Hearing, Vision
•GABA <sub>B</sub>	1	Brain	Neurotransmitter	Mood Disorders
•Extracellular Calcium Sensing	1	Parathyroid, Kidney, GI Tract	Calcium Regulation	Cataracts, GI Tumors

Figure 1, pg. 3 of 3

	A	B	C
1	<b>GPCR Agonist</b>	<b>Generic Name</b>	<b>Brand Name</b>
97			
98	<b>Acetylcholine</b>	Bethanechol	Generic
99	Muscarinic AC	Pilocarpine	Salagen
100	Muscarinic AC	Levetiracetam	Keppra
101			
102	<b>Dopamine</b>		
103	Dopamine (mixed)	Dopamine	Intropin
104	D1	Femoldopam	Corlopam
105	D2	Apomorphine	Ixense
106	D2/D3	Ropinirole	Requip
107	D2/D3	Pramipexole	Mirapex
108	D2/D3	Amisulpride	Solian
109	D2 Type	Bromocriptine	Parlodel
110	D1/D2	Pergolide	Permax
111			
112	Prostaglandin F2a (PG F2a)	Latanoprost	Xalatan
113	Prostaglandin F2a (PG F2a)	Unknown	Travatan
114	Prostaglandin E1 (PGE1)	Alprostadil	Befar
115			
116	Gonadotropin-releasing hormone (GnRH)	LHRH agonist	TRELSTAR LA
117	GnRH	Leuprolide	Lupron Depot
118			
119			
120	Calcitonin	Calcitonin	
121		<b>Fig 3, page 3 of 3</b>	

**Figure 2****G protein-coupled receptors:**

(Division into Class A

Or Class B)

1. **A1 adenosine receptor** [Homo sapiens]. ACCESSION AAB25533  
npivyaf riqkfrvfl kiwndhfrq pappededlp eerpdd  
Class A
2. **adrenergic, alpha -1B-, receptor** [Homo sapiens]. ACCESSION NP\_000670  
npiiypcsskefkrafvrlgcqcrgrgrrrrrrrlggcaytyrpwtrggslersqsrkdslddsgsclsgsqrtilpsaspspgylrggap  
ppvelcafpewkapgallsipapeppgrgrhdsgplfifklltepespgtdggasnggceaaadvangqpgfksnmplapgqf  
Class A
3. **adrenergic receptor alpha-2A** [Homo sapiens]. ACCESSION AAG00447  
npviytifnhdfirafkkilcrgdrkriv  
Class A
4. **alpha-2B-adrenergic receptor** - human. ACCESSION A37223  
npviytifnqdfirafrrilcrpwtqtaw  
Class A
5. **alpha-2C-adrenergic receptor** - human. ACCESSION A31237  
npviytvfnqdfirpsfkhlfrmrgrfq  
Class A
6. **beta-1-adrenergic receptor** [Homo sapiens]. ACCESSION NP\_000675  
npiiyerspdrkafqglccarraarrhathgdrprasgclarppppsgaasdddddvvgatpparllpewagcnggaaads  
dssldeprpghaseskv  
Class A
7. **beta-2 adrenergic receptor**. ACCESSION P07550  
npliyerspdrkafqglccarraarrhathgdrprasgclarppppsgaasdddddvvgatpparllpewagcnggaaads  
sll  
Class A
8. **dopamine receptor D1** [Homo sapiens]. ACCESSION NP\_000785  
npiiyafnadfrkafstllgcyrllcpatnnaietvsinnngaamfsshheprgsiskecnlyliphavgssedlkkeaagiarplekls  
palsvildytdvslekiqpitqngqhpt  
Class A
9. **D(2) dopamine receptor**. ACCESSION P14416  
npiiyttfniefrkafkilkhc  
Class A

10. **d3 dopamine receptor** - human. ACCESSION G01977  
npviyttfniefkafkilsce  
Class A
11. **dopamine receptor D4** - human. ACCESSION DYHUD4  
npviytfvinaefrnvfrkalracc  
Class A
12. **dopamine receptor D5** - human. ACCESSION DYHUD5  
npviyafnadfqkvfaqlgcshfcsrtpvetvnisnelisynqdivfhkeiaaayihmmpnavtpgnrevdndeeegpfdrmfqi  
yqtspdgdppvaesvwelcgeisldkitpftpngfh  
Class A
13. **muscarinic acetylcholine receptor M1** [Homo sapiens]. ACCESSION NP\_000729  
nrmcyalcnkafrdtfrllllcrwdkrrwrkipkrpgsvhrtpsraqc  
Class A
14. **muscarinic acetylcholine receptor M2** [Homo sapiens]. ACCESSION NP\_000730  
npacyalcnatfkktfkhlmlmchyknigatr  
Class A
15. **muscarinic acetylcholine receptor M3** [Homo sapiens].  
npvcyalcnktfirtfkmlllcqcdkkrrkqqyqqrqsvifhkrpeqal  
Class A
16. **muscarinic acetylcholine receptor M4** [Homo sapiens]. ACCESSION NP\_000732  
npacyalcnatfkktftrhlllcqymnigtar  
Class A
17. **m5 muscarinic receptor**. locus HUMACHRM ACCESSION AAA51569  
npicyalcnrtfrktfkmlllcrwkkkkveeklywqgnsklp  
Class A
18. **5-hydroxytryptamine (serotonin) receptor 1A** [Homo sapiens]. ACCESSION BAA90449  
npviyayfnkdfqnafkkiickcf  
Class A
19. **5-hydroxytryptamine (serotonin) receptor 1B** [Homo sapiens]. ACCESSION BAA94455  
npiiytmsnedfkqafhklirfkcts  
Class A
20. **5-hydroxytryptamine (serotonin) receptor 1E** [Homo sapiens]. ACCESSION BAA94458  
npilytsfmedfklaflklircre  
Class A
21. **OLFACTORY RECEPTOR 6A1**. ACCESSION O95222

Figure 2  
page 3


- npiiyclrnqevkralccilhlyqhdpdpkkgsmv  
**Class A**
22. **OLFACTORY RECEPTOR 2C1**. ACCESSION O95371  
nplytlrnmevkgalrrllgkgrevg  
**Class A**
23. **angiotensin receptor 1 [Homo sapiens]**. ACCESSION NP\_033611  
nplfygflgkckfryflqllkyippkakshsnlstkmsflsyrpsdnvssstkkpapcfeve  
**Class B**
24. **angiotensin receptor 2 [Homo sapiens]**. ACCESSION NP\_000677  
nplfyfcvgnrfqqlrsvfrvpitwlqgkresmscrkssslremetfvs  
**Class B**
25. **interleukin 8 receptor beta (CXCR2) [Homo sapiens]**. ACCESSION NM\_001557  
NPLYAFIGQKFRHGLLKILAIHGLISKDSLPKDSRPSFVGSSSGHTSTTL  
**Class B**
26. **cx3c chemokine receptor 1 (cx3cr1) (fractalkine receptor)**  
ACCESSION P49238  
nplyafagekfrlylyhlygkclavlcgrsvhvfsssesqrsrhgsvlssnfty.nts dgdallll  
**Class B**
27. **neurotensin receptor - human**. ACCESSION S29506  
n pilynlvsanfrhiflatlaclcpvwrtrkrpafsrkadsvssnhflssnatretly  
**Class B**
28. **SUBSTANCE-P RECEPTOR (SPR) (NK-1 RECEPTOR) (NK-1R)**. ACCESSION P25103  
npiiyccldrfrlglkhafrccpfisagdyeglemkstrylqtqgsvykvsrlettistvvgaaheepedgpkatpssldltsncssrsd  
sktmtesfsfssnvl  
**Class B**
29. **vasopressin receptor type 2 [Homo sapiens]**. ACCESSION AAD16444  
npwiyasfsssvselrslccargtrppslgpqdesctfassslakdtss  
**Class B**
30. **thyrotropin-releasing hormone receptor - human**. ACCESSION JN0708  
npviynlmsqkfraafrklcnckqkptekpanysvalnysvikesdhfsteldclitvtdtylsafkvsfddtclasevsfsqs  
**Class B**
31. **oxytocin receptor - human**. ACCESSION A55493  
npwiymlftghlfhelvqrfllccsasykgrlgetsaskksnsssfvlshrssscrsccqpsta  
**Class B**


Figure 2  
page 4


32. **neuromedin U receptor 1 [Homo sapiens].** ACCESSION AAG24793  
npvlylmsrfrfretfqaclclgacchrlrprhsshslsrmttgstlcdvgsllgswvhplagndgpeaqgetdps  
**Class B**
33. **gastrin receptor.** ACCESSION AAC37528  
nplvycfmhrrfrqacletcarccprprarpralpdedpptpsiaslsrlsyttistlgpg  
**Class B**
34. **galanin receptor 3 [Homo sapiens].** ACCESSION 10879541  
nplyvalasrhfrarfrirlwpcgrrrrhrarralrrvrpassgppgcpdarpsgrllagggqgpepregpvhggeaargpe  
**Class A**
35. **edg-1 - human.** ACCESSION A35300  
npiiytltnkemrrafirimsckcpsgdsagkfkriiagmefsrksdnnshpqkdegdnpetimssgnvnsss  
**Class A**
36. **central cannabinoid receptor [Homo sapiens].** ACCESSION NP\_057167  
npiiyalrskdlrhafmsfpcgegtacpldnsmgdsdclhkhannaasvhraaesckstvkiakvtnsvstdtsaeal  
**Class A**
37. **delta opioid receptor - human.** ACCESSION I38532  
npvlyafldenfkrcfrqlcrkpcgrpdpsfsrpreatarervtactpsdgpqggraa  
**Class A**
38. **proteinase activated receptor 2 (PAR-2) human.** ACCESSION P55085  
dpfvyyfvdhfrdhaknallcrsvrtvkqmqltskkhrksssysssttktsy  
**Class B**
39. **vasopressive intestinal peptide receptor (VIPR) rat.** ACCESSION NM\_012685  
NGEVQAELRRKWRRWHLQGVLGWSSKSQHPWGGSNATCSTQVSMLTRVSPSARR  
SSSFQAEVSLV  
**Class B**


	A	B	C
1	<b>GPCR Agonist</b>	<b>Generic Name</b>	<b>Brand Name</b>
2	<b>5-HT</b>		
3	5-HT-1B/1D	Zolmitriptan	Zomig
4		Rizatriptan	Maxalt
5		Eletriptan	Relpax
6		Trazodone	Desyrel
7	5-HT-1D	Sumatriptan	Imitrex (P)
8		Naratriptan	Amerge
9		Almotriptan	Axert
10	5-HT-1B/1A	Frovatriptan	Frova
11			
12	5-HT-1A	Buspirone	BuSpar
13	5-HT-1A	Buspirone	Generic
14	5-HT-1A	Ziprasidone	Geodon
15			
16	5-HT-4	Tegaserod	Zelnorm
17	5-HT-4	Mosapride	Gasmotin
18	5-HT-4	Cisapride	Propulsid
19			
20	5-HT-2A/2C	Clozapine	Clozaril
21			
22	5-HT-2 / Dopa D1	Femoldopam	Corloпам
23			
24	5-HT/ Opioid u	Tramadol	Ultram
25	5-HT/ Opioid u	Tramadol	Ultracet
26	5-HT/ Opioid u	Tramadol	Generic
27			
28	<b>Opioid</b>		
29	Opioid	Codeine	Generic
30		Hydrocodone	Generic
31		Hydromorphone	Dilaudid
32		Levorphanol	Levo-Dromoran
33		Morphine	MS Contin
34		Morphine	Generic
35		Oxycodone	OxyContin
36		Oxycodone/APAP	Generic
37		Oxymorphone	Numorphan
38		Alfentanil	Alfenta
39		Fentanyl	Duragesic
40		Fentanyl	Sublimaze
41		Meperidine	Demerol
42		Sufentanil	Sufenta
43		Levomethadyl	Orlaam
44		Methadone	Dolophine
45		Propoxyphene	Darvon
46		Buprenorphine	Transtec
47		Remifentanil	Ultiva
48			
49	5-HT/ Opioid u	Tramadol	Ultram
50	5-HT/ Opioid u	Tramadol	Ultracet
51	5-HT/ Opioid u	Tramadol	Generic
52		<b>Fig 3, page 1 of 3</b>	


	A	B	C
1	<b>GPCR Agonist</b>	<b>Generic Name</b>	<b>Brand Name</b>
53	<b>ADO</b>		
54	ADO (mixed)	Adenosine	Adenocard
55		Adenosine	Adenoscan
56			
57	<b>Adrenoceptor</b>		
58	Adrenoceptor	Methylphenidate	Generic
59	Beta (mixed)	Isoproterenol	Isuprel
60		Ephedrine	Generic
61		Mephentermine	Wyamine
62	Beta-1	Norepinephrine	Levophed
63			
64	Beta-2	Salmeterol	Serevent
65		Salmeterol/ fluticasone	Advair
66		Albuterol, Aerosol	Generic
67		Albuterol, Sulfate	Generic
68		Albuterol	Proventil
69		Bitolterol	Tornalate
70		Isoetharine	Isoetharine
71		Metaproterenol	Alupent
72		Pirbuterol	Maxair
73		Formoterol	Foradil
74		Formoterol,	Oxis
75		Albuterol	Ventolin HFA
76		Bambuterol	Bambec
77		Salbutamol	Inspiryl Turbuhaler
78		Terbutaline	Brethine
79		Terbutaline	Terbutaline
80	H1 (-) / Beta-2 (+)	loratadine/ pseudoephedrine	Claritin-D
81	H1 (-) / Beta-2 (+)	Fexofenadine/ pseudoephedrine	Allegra-D
82		Terbutaline	Brethine
83	Alpha-Beta (mixed)	Metaraminol	Aramine
84		Epinephrine	Generic
85	Alpha (mixed)	Methoxamine	Vasoxyl
86		Phenyephrine	Neo-Synephrine
87	Alpha-1	Modafinil	Provigil
88		Midodrine	ProAmatine
89			
90	Alpha-2	Guanfacine	Tenex
91		Tizanidine SR	Sirdalud CR
92		Moxonidine	Physiotens
93		Dexmedetomidine	Precedex
94		Brimonidine	Alphagen
95		Apraclonidine	Iopidine
96		<b>Fig 3, page 2 of 3</b>	












































Fig. 5-E

Fig. 5-F








Fig. 5-G


Fig. 5-H






































Fig 6-I

Fig 6-J














Fig 6-Q


Fig 6-R


























Fig 7-K

Fig 7-L












Fig 7-S

Fig 7-I








Fig 8-A

Fig 8-B




Fig 8-C

Fig 8-D